

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2006, 19:09:15 ; Search time 39 Seconds
(without alignments)
394.735 Million cell updates/sec

Title: US-10-816-698-3

Perfect score: 809

Sequence: 1 MSEVRPLSRDILMETLLYEQ.....LLALLALLPLLSGGHLLK 160

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR 80: *
1: PIR1: *
2: PIR2: *
3: PIR3: *
4: PIR4: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	809	100.0	160	2 S58214	apoptosis inducer
2	97.5	12.1	509	2 G87596	tryptophan halogen
3	83.5	10.3	373	1 DERTH2	3beta-hydroxy-Delt
4	82	10.1	675	1 H69200	heavy-metal transp
5	81.5	10.1	373	1 DERTHM	3beta-hydroxy-Delt
6	81.5	10.1	635	2 S16567	beta-1,4-D-xylanas
7	80.5	10.0	633	2 S76749	hypothetical prote
8	78	9.6	431	2 S50633	hypothetical prote
9	77	9.5	1092	2 T12520	hypothetical prote
10	77	9.5	1173	2 H83189	DNA polymerase III
11	76.5	9.5	1004	1 S55353	probable copper-tr
12	76	9.4	406	2 B81391	zinc proteinase-li
13	75	9.3	320	2 S07384	diaminopimelate de
14	75	9.3	655	2 AD2422	DNA polymerase III
15	74.5	9.2	172	2 AF0109	flavodoxin 2 (impo
16	74.5	9.2	447	2 T46128	hypothetical prote
17	74	9.1	389	2 S38359	ribosomal protein
18	73.5	9.1	171	2 AE0350	conserved hypothet
19	73	9.0	404	2 A72496	hypothetical prote
20	72.5	9.0	321	2 T01521	syn-taxin homolog 1
21	72.5	9.0	490	2 E96010	probable two-compo
22	72.5	9.0	615	2 S58230	transcription init
23	72	8.9	1048	1 BVECS	exonuclease (EC 3.
24	71.5	8.8	343	2 C89779	hypothetical prote
25	71.5	8.8	389	2 E96498	L3 cytoplasmic rib
26	71.5	8.8	617	2 AF1284	5-methyltetrahydro
27	71.5	8.8	677	2 B71306	hypothetical prote
28	71.5	8.8	857	2 F84227	molybdenum-binding
29	71	8.8	217	2 B83643	conserved hypothet

30	71	8.8	322	2 F83300	probable enoyl-CoA
31	71	8.8	391	2 C71499	probable gen. secr
32	71	8.8	799	2 S55656	ribonucleoside-dip
33	71	8.8	1953	2 T40642	probable helicase
34	70.5	8.7	253	2 B69758	conserved hypothet
35	70.5	8.7	350	2 C83608	probable transcrip
36	70.5	8.7	390	2 C86641	60s ribosomal prot
37	70.5	8.7	390	2 JQ0772	ribosomal protein
38	70.5	8.7	1156	2 JQ0775	phytochrome B - so
39	69.5	8.6	188	2 T34881	hypothetical prote
40	69.5	8.6	525	2 H69229	phosphoglycerate d
41	69.5	8.6	674	2 S75662	sensory transducti
42	69.5	8.6	675	2 S59379	probable membrane
43	69.5	8.6	822	2 T00269	hypothetical prote
44	69.5	8.6	910	2 B89918	2-oxoglutarate deH
45	69	8.5	345	2 C72760	probable heme expo

ALIGNMENTS

RESULT 1

S58214

apoptosis inducer NBK - human

C:Species: Homo sapiens (man)

C>Date: 13-Jan-1996 #sequence_revision 01-Mar-1996 #text_change 09-Jul-2004

C:Accession: S58214; G02437

R.Pun, K.T.; Farrow, S.N.; Raven, T.; Wride, C.J.; White, J.H.M.; Brown, R.

submitted to the EMBL Data Library, July 1995

A:Description: E1B-19K interacts with a novel apoptotic inducer, NBK.

A:Reference number: S58214

A:Accession: S58214

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-160 <PUN>

A:Cross-references: UNIPROT:Q13323; UNIPARC:UPI000000D929; EMBL:X89986; NID:g929654; PID

R.Han, J.

submitted to the EMBL Data Library, February 1996

A:Reference number: H01273

A:Accession: G02437

A>Status: preliminary; translated from GB/EMBL/DBBJ

A:Molecule type: mRNA

A:Residues: 1-160 <HAN>

A:Cross-references: UNIPARC:UPI000000D929; EMBL:U49730; NID:g1229145; PID:g1229146

C:Keywords: apoptosis

Query Match 100.0%; Score 809; DB 2; Length 160;
Best Local Similarity 100.0%; Pred. No. 9.9e-71;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

Db 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

QY 61 LACIGDMDVSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120

Db 61 LACIGDMDVSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120

QY 121 FWRSPNPGSVWVCEQVLLALLLALLLPLLSGGLHLK 160

Db 121 FWRSPNPGSVWVCEQVLLALLLALLLPLLSGGLHLK 160

RESULT 2

G87596

tryptophan halogenase, probable [imported] - Caulobacter crescentus

C:Species: Caulobacter crescentus

C>Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 09-Jul-2004

C:Accession: G87596

R;Nierman, W.C.; Feldblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg, J.

B.; Laub, M.T.; DeBois, R.T.; Dodson, R.J.; Durkin, A.S.; Gwinn, M.L.; Haft, D.H.; Kolon

n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C.M.

Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001

RESULT 6

SI6567
beta-1,4-D-xylanase - Butyrivibrio fibrisolvens
C:Species: Butyrivibrio fibrisolvens
C:Date: 21-Nov-1993 #sequence_revision 26-May-1995 #text_change 09-Jul-2004
C:Accession: SI6567
R:Lin, L.L.; Thomson, J.A.
Mol. Gen. Genet. 228, 55-61, 1991
A:Title: Cloning, sequencing and expression of a gene encoding a 73 kDa xylanase enzyme
A:Reference number: SI6567; MUID:91360090; PMID:1909424
A:Accession: SI6567
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-635 <LIN>
A:Cross-references: UNIPROT:P26223; UNIPARC:UPI000013908D; EMBL:X61495; NID:948962; PIDN
A:Note: the authors translated the codon CTT for residue 131 as Asp and GAT for residue
F:30-338/Domain: Streptomyces endo-1,4-beta-xylanase A homology <SXY>

Query Match 10.1%; Score 81.5; DB 2; Length 635;
Best Local Similarity 25.0%; Pred. No. 7.1;
Matches 33; Conservative 28; Mismatches 48; Indels 23; Gaps 7;

QY 5 RPLSRDILMETLLYEQLLEPPTMEVLGMDTS--EDLDPMEDFDSLECMGSDALALRLA 62
DB 197 QWKQDFILEKVL-CPLDKLIDGMQSHLLMHPDISEVRTALE-MYGSTGLQIHIT 254
QY 63 CIGDEMVSRLAPRLAQISEVAMHSLGLAFIYDQTEIRDVLRSFMDGFTTLKENI--MR 120
DB 255 ---ELDMHNADP-----SESMHALATRY-----QEPFQTYLDAKKSGKANITSTV 297
QY 121 FWRSPNPGSWVS 132
DB 298 FWNLLDENSWSL 309

RESULT 7

S76749
hypothetical protein - Synecocystis sp. (strain PCC 6803)
C:Species: Synecocystis sp.
A:Variety: PCC 6803
C:Date: 25-Apr-1997 #sequence_revision 25-Apr-1997 #text_change 09-Jul-2004
C:Accession: S76749
R:Kaneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.;
O, K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda
DNA Res. 3, 109-136, 1996
A:Title: Sequence analysis of the genome of the unicellular cyanobacterium Synecocystis
S.

A:Reference number: S74322; MUID:97061201; PMID:8905231
A:Accession: S76749
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-633 <KAN>
A:Cross-references: UNIPROT:P74554; UNIPARC:UPI00000C0E94; EMBL:D90916; GB:AB001339; NID
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1996

Query Match 10.0%; Score 80.5; DB 2; Length 633;
Best Local Similarity 23.8%; Pred. No. 8.8;
Matches 43; Conservative 26; Mismatches 45; Indels 67; Gaps 8;

QY 1 MBEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTS--EDLDPMEDFDSLECMGSDAL 57
DB 120 LSVQVDRSQD-----TSEQILQ--AIAVLRTQVGNQSNLILDP--DLDSYYLME---AL 166
QY 58 ALR-----LACIG-----DEMDSVRAPRLAQISEVAMHSLGLAFIYDQ 96
DB 167 LKLPOLQTLDAQGHIIITAHSGFGLSPAESQVLVIKAQLKTSLVNLCVATHTNA 226
QY 97 TEDIRDVLRSFMDGFTTLKE-----NTMRFWRSPN 126
DB 227 RQQLPRVINSGLNLTITVLEELRQSLTKVITGQIKLNDALNQCSQWGLLSLHFWRLVS 286

QY 127 P 127
DB 287 P 287

RESULT 8

S50633
hypothetical protein YER130c - yeast (Saccharomyces cerevisiae)
C:Species: Saccharomyces cerevisiae
C:Date: 28-May-1993 #sequence_revision 24-Feb-1995 #text_change 19-Apr-2002
C:Accession: S50633
R:Dieterich, F.S.
submitted to the EMBL Data Library, December 1994
A:Description: The sequence of S. cerevisiae cosmids 9781, 8198, 9115, 9981, and lambda da

A:Reference number: S50437
A:Accession: S50633
A:Molecule type: DNA
A:Residues: 1-431 <DIE>
A:Cross-references: UNIPARC:UPI0000017CCA8; EMBL:U18916; GSPDB:GN000005; MIPS:YER130C
C:Genetics:
A:Gene: MIPS:YER130C
A:Cross-references: SGD:S00000932
A:Map position: 5R

Query Match 9.6%; Score 78; DB 2; Length 431;
Best Local Similarity 25.4%; Pred. No. 9.7;
Matches 35; Conservative 21; Mismatches 42; Indels 40; Gaps 7;

QY 28 EVLGWTDSEEDL---DPMEDFDSLECMGSDALALRLACIGDEMVSRLAPRLAQ----- 79
DB 103 EFFGRRELNEPLFNNDIVENDDDDLNNEVDVLMVS-----DDELVNERFSLKQKQPLDG 158
QY 80 -----LSEVAMHSLGLAFIYDQTEIRDVLRSFMDGFTTL---KENIMRFPWR----- 123
DB 159 LNRISSTNVLKNLEIHE-----FIIDPTENIDDELE---DSFTTVPSQKKKVRDYFKLNIF 211
QY 124 -----SPNPGSWVSCEQV 136
DB 212 GSSSSNNNSNLSLGEPI 229

RESULT 9

T12520
hypothetical protein DKFZp434G173.1 - human
C:Species: Homo sapiens (man)
C:Date: 23-Jul-1999 #sequence_revision 23-Jul-1999 #text_change 23-Jul-1999
C:Accession: T12520
R:Wambutt, R.; Heubner, D.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, June 1999
A:Reference number: Z17524
A:Accession: T12520
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-1092 <WAM>
A:Cross-references: UNIPARC:UPI00000711F2; EMBL:AL080133
A:Experimental source: adult testis; clone DKFZp434G173
C:Genetics:

A:Note: DKFZp434G173.1

Query Match 9.5%; Score 77; DB 2; Length 1092;
Best Local Similarity 24.8%; Pred. No. 36;
Matches 33; Conservative 22; Mismatches 44; Indels 34; Gaps 5;

QY 19 EQLLEPPTMEVLGMDTSSEEDLDPMEDFDSLECMGSDALALRLACIGDEMVSRLAPRL 77
DB 961 KQLREQVSQDLMALQGTQNPASFLPSFDEVDS-----GDQPPATSVAPRA 1006
QY 78 AOLSEVAMHSLGLAFIYDQTEIRDVLRSFMDGFTTLKENIM-RFWRSPNPGSWVSCEQV 136
DB 1007 KQFRAV-----RTTEGEETESRVFGSTPQRSFSLSRVYRALP-----LQL 1048
QY 137 LLALLLLALLLP 149
|| ||||| |||

Db 1049 LLLLLLLACLPL 1061

RESULT 10

H83189

DNA polymerase III, alpha chain PA3640 [imported] - Pseudomonas aeruginosa (strain PA01)

C:Species: Pseudomonas aeruginosa

C>Date: 15-Sep-2000 #sequence_revision 15-Sep-2000 #text_change 09-Jul-2004

C:Accession: H83189

R:Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warrenner, P.; Hickey, M.J.; Bz

adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Latbig, K.; Lim,

.; Lozy, S.; Olson, M.V.

Nature 406, 959-964, 2000

A:Title: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic patho

A:Reference number: A82950; MUID:2043737; PMID:10984043

A:Accession: H83189

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-1173 <STO>

A:Cross-references: UNIPROT:Q9HXZ1; UNIPARC:UPI00001296DE; GB:AE004784; GB:AE004091; NID

A:Experimental source: strain PA01

C:Genetics:

C:Superfamily: DNA-directed DNA polymerase III alpha chain

Query Match 9.5%; Score 77; DB 2; Length 1173;

Best Local Similarity 25.2%; Pred. No. 40;

Matches 33; Conservative 21; Mismatches 33; Indels 44; Gaps 6;

Qy 1 MSEVRPLSRDILMETLLEQLLEPTMEVLGMDTSEEDLDPMDPFDLSLECMGSD----- 55

Db 377 ITDIDPLAYD-----LIFERFLNERTS-----MPDFVDVFCMEGRDVIDY 418

Qy 56 -----ALALRLACIGDMVDVSLAPRLA-QLSEVAMHSIGLAP--IYD 95

Db 419 VADAYGRNAVQIITFTGTTAAK-AVRDVARVQKSYGLADRLSKMTIPFVGMGLDKAYE 477

Qy 96 QTEDIRDVLRS 106

Db 478 QEMLRDLFLKS 488

RESULT 11

S55353

probable copper-transporting ATPase (EC 3.6.1.-) - yeast (Saccharomyces cerevisiae)

N:Alternate names: protein P9954.6; protein YDR270w

C:Species: Saccharomyces cerevisiae

C>Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 09-Jul-2004

C:Accession: S55353; S70129; S48298

R:Fu, D.; Beeler, T.J.; Dunn, T.M.

Yeast 11, 283-292, 1995

A:Title: Sequence, mapping and disruption of CCC2, a gene that cross-complements the Ca

A:Reference number: S55353; MUID:95304841; PMID:7785328

A:Accession: S55353

A:Molecule type: DNA

A:Residues: 1-1004 <FUD>

A:Cross-references: UNIPROT:P38995; UNIPARC:UPI000012663A; EMBL:L36317; NID:9538514; PID

R:Le, T.

submitted to the EMBL Data Library, May 1996

A:Description: The sequence of S. cerevisiae cosmid 9954.

A:Reference number: S70124

A:Accession: S70129

A:Molecule type: DNA

A:Residues: 1-1004 <LET>

A:Cross-references: UNIPARC:UPI000012663A; EMBL:U51030; NID:gi332633; PIDN:AAB64451.1; F

C:Genetics:

A:Gene: SGD:CCC2; MIPS:YDR270w

A:Cross-references: SGD:S0002678; MIPS:YDR270w

A:Map position: 4R

C:Superfamily: yeast copper-transporting ATPase; ATPase nucleotide-binding domain homolo

C:Keywords: ATP; copper transport; hydrolase; ion transport; metal binding; transmembran

F:8-37/Domain: heavy-metal-associated homology <HMA1>

F:86-115/Domain: heavy-metal-associated homology <HMA2>

F:262-278/Domain: transmembrane #status predicted <TM1>

F:304-320/Domain: transmembrane #status predicted <TM2>

F:308-376/Domain: ATPase transduction domain homology <ATT>

F:340-356/Domain: transmembrane #status predicted <TM3>

F:533-549/Domain: transmembrane #status predicted <TM4>

F:574-590/Domain: transmembrane #status predicted <TM5>

F:757-909/Domain: ATPase nucleotide-binding domain homology <ATN>

F:905-921/Domain: transmembrane #status predicted <TM6>

F:934-950/Domain: transmembrane #status predicted <TM7>

F:11,13,16/Binding site: copper (Met, Cys, Cys) #status predicted

F:89,91,94/Binding site: copper (Met, Cys, Cys) #status predicted

Query Match 9.5%; Score 76.5; DB 1; Length 1004;

Best Local Similarity 23.08; Pred. No. 37;

Matches 37; Conservative 33; Mismatches 38; Indels 53; Gaps 9;

Qy 33 TDSIEDLPMD--FDSLECMGSD-----DALALRLACIGDE---- 67

Db 129 TLTETAREMIEDCGFDSNIIMDGNADMTKTVLKVKAFEDSEPLILSSVSERQFL 188

Qy 68 MDVSLRAPRLAQSEVAMHSIGLAFIYDQTEDIRDVL------SFMGDFITL- 114

Db 189 LDGKSKSISD---DMHTLTIKYCCNEL-GIRDLRLHLERTGYKTFVSNLNDTTQLR 243

Qy 115 ---KENIMRFRSPNPGSVSWSCQVLLALL-LIALLPL 151

Db 244 LLSKEDIRFWKN-----SIKSTLLAIICMLLYMIVPM 278

RESULT 12

B81391

zinc proteinase-like protein Cj0463 [imported] - Campylobacter jejuni (strain NCTC 11168)

C:Species: Campylobacter jejuni

C>Date: 31-Mar-2000 #sequence_revision 31-Mar-2000 #text_change 09-Jul-2004

C:Accession: B81391

R:Parkhill, J.; Wren, B.W.; Mungall, K.; Ketley, J.M.; Churcher, C.; Basham, D.; Chilling

C.W.; Quail, M.; Rajandream, M.A.; Rutherford, K.M.; VanVliet, A.; Whitehead, S.; Barrell

Nature 403, 665-668, 2000

A:Title: The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hyp

A:Reference number: A81250; MUID:20150912; PMID:10688204

A:Accession: B81391

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-406 <PAR>

A:Cross-references: UNIPROT:Q9PI45; UNIPARC:UPI000000C213D; GB:AL139075; GB:AL111168; NID:

A:Experimental source: serotype O2, strain NCTC 11168

C:Genetics:

A:Gene: Cj0463

Query Match 9.4%; Score 76; DB 2; Length 406;

Best Local Similarity 23.5%; Pred. No. 14;

Matches 31; Conservative 28; Mismatches 37; Indels 36; Gaps 5;

Qy 47 SLECMGSDALALRLACIGDMVDVSLRA-----PRLAQ--LSEVAMHSIGLAFIYDQT 97

Db 69 NLEASSGFESLEINSLCNFNDFALKSLKLLKPRIEEKTLQKLKINALG----- 120

Qy 98 EDIRDVLRSFMDGFTTLKENIM-----RPWRSPNPGSVSWSCQVLLALL-----LL 143

Db 121 -----ELASKNSDPDYLAKNLLNAQIFPKCKEFQSPNDGDEKSIETLSLKDLQNFYKNFIH 175

Qy 144 LALLPLLSGGL 155

Db 176 LSDLVILGGDL 187

RESULT 13

S07384

diaminopimelate dehydrogenase (EC 1.4.1.16) - Corynebacterium glutamicum

C:Species: Corynebacterium glutamicum

C>Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004

C:Accession: S07384

R:Ishino, S.; Mizukami, T.; Yamaguchi, K.; Katsumata, R.; Araki, K.

RESULT 15
AF0109
flavodoxin 2 (imported) - Yersinia pestis (strain C092)

THIS PAGE BLANK (USPTO)

This Page Blank (uspto)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2006, 19:05:54 ; Search time 229 Seconds
(without alignments)
492.946 Million cell updates/sec

Title: US-10-816-698-3
Perfect score: 809
Sequence: 1 MSEVRPLSRDLMTLLYEQ.....LLLLALLPLSLGGHLHLK 160

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt 05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	809	100.0	160	1 BIK HUMAN	Q13323 homo sapien
2	809	100.0	160	2 Q6FH93_HUMAN	Q6FH93 homo sapien
3	301	37.2	158	2 Q925D2_RAT	Q925D2 rattus norv
4	291	36.0	158	2 Q99L97_MOUSE	Q99L97 mus musculu
5	284	35.1	150	2 Q70337_MOUSE	Q70337 mus musculu
6	97.5	12.1	509	2 Q9A4M3_CAUCR	Q9A4M3 caulobacter
7	94.5	11.7	678	2 Q72WM4_DESVH	Q72WM4 desulfovibr
8	85.5	10.6	405	2 Q7PK12_ANOGA	Q7PK12 anopheles g
9	85	10.5	2004	2 Q4WGN9_ASFPF	Q4WGN9 aspergillus
10	84.5	10.4	705	2 Q70C70_STRTR	Q70C70 streptococc
11	84	10.4	1120	2 Q9VUK6_DROME	Q9VUK6 drosophila
12	84	10.4	2726	2 Q6UBD8_DROME	Q6UBD8 drosophila
13	83.5	10.3	265	1 CAD10_MOUSE	Q7P408 mus musculu
14	83.5	10.3	329	2 Q7P233_GIALA	Q7P233 giardia lam
15	83.5	10.3	372	1 3BHS2_RAT	F22072 r 3 beta-hy
16	82.5	10.2	167	2 Q5P8D1_AZOSE	Q5P8D1 azoarcus sp
17	82.5	10.2	705	2 Q4KTJ3_LACT	Q4KTJ3 lactococcus
18	82.5	10.2	705	2 Q4LEN1_LACT	Q4LEN1 lactococcus
19	82.5	10.2	705	2 P94888_LACT	P94888 lactococcus
20	82.5	10.2	705	2 Q9FB71_LACLA	Q9FB71 lactococcus
21	82.5	10.2	705	2 Q7AY49_STRTR	Q7AY49 streptococc
22	82.5	10.2	705	2 Q926K0_LISIN	Q926K0 listeria in
23	82.5	10.2	964	2 Q9NV77_HUMAN	Q9NV77 homo sapien
24	82.5	10.2	1045	2 Q9NVW1_HUMAN	Q9NVW1 homo sapien
25	82.5	10.2	1769	2 Q9P273_HUMAN	Q9P273 homo sapien
26	82.5	10.2	1828	2 Q80TD2_MOUSE	Q80TD2 mus musculu
27	82.5	10.2	2346	2 Q9JLC1_MOUSE	Q9JLC1 mus musculu
28	82.5	10.2	2715	2 Q9WTS6_MOUSE	Q9WTS6 mus musculu
29	82	10.1	675	2 Q26849_METTH	Q26849 methanobact
30	82	10.1	1199	2 Q7UUS6_RHOBA	Q7UUS6 rhodospirell
31	81.5	10.1	247	2 Q4RUG4_TETNG	Q4RUG4 tetraodon n

32	81.5	10.1	635	1 XYNB_BUTFI	P26223 butyrivibri
33	81.5	10.1	806	2 Q5UMB2_HALMA	Q5UMB2 haloarcula
34	81.5	10.1	1710	2 Q6FPU9_CANGA	Q6FPU9 candida gla
35	80.5	10.0	633	2 P74554_SYNY3	P74554 synchocyst
36	80.5	10.0	732	2 Q4SENO_TETNG	Q4SENO tetraodon n
37	80	9.9	352	2 Q5FFV9_BHRRG	Q5FFV9 ehrlichia r
38	80	9.9	352	2 Q5FD77_EHRRW	Q5FD77 ehrlichia r
39	80	9.9	352	2 Q5HAF9_EHRRW	Q5HAF9 ehrlichia r
40	80	9.9	1928	2 Q5GA85_9RHAB	Q5GA85 taro vein c
41	79.5	9.8	444	2 Q8TX27_METKA	Q8TX27 methanopyru
42	79.5	9.8	809	2 Q72JJ6_THET2	Q72JJ6 thermus the
43	79.5	9.8	1390	2 Q5JHB6_PVRKO	Q5JHB6 pyrococcus
44	79	9.8	204	2 Q6GZX0_FRG3V	Q6GZX0 frog virus
45	79	9.8	278	2 Q5Y3Q1_9NEOP	Q5Y3Q1 fahrenheitz

ALIGNMENTS

RESULT 1

BIK_HUMAN

ID_BIK_HUMAN STANDARD; PRT; 160 AA.

AC Q13323; Q16582;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DE 13-SEP-2005 (Rel. 48, Last annotation update)

DE Bcl-2 interacting killer (Apoptosis inducer NBK) (BP4) (BIP1).

CN Name=BIK; Synonyms=NBK;

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OX NCBI_TaxID=9606;

RP [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=B-cell;

RX MEDLINE=96068922; PubMed=7478623;

RA Boyd J.M., Gallo G.J., Bhangovan B., Houghton A.B., Malstrom S.,

RA Avery B.J., Ebb R.G., Subramanian T., Chittenden T., Lutz R.J.,

RA Chinnadurai G.;

RT "Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins.";

RT Oncogene 11:1921-1928(1995).

RL [2]

RP NUCLEOTIDE SEQUENCE.

RX MEDLINE=96413338; PubMed=8816500;

RA Han J., Sabbatini P., White E.;

RT "Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with B1B 19K.";

RL Mol. Cell. Biol. 16:5857-5864(1996).

RL [3]

RP NUCLEOTIDE SEQUENCE [MRNA].

RC TISSUE=Lymphoid;

RA Pun K.-T., Farrow S.N., Raven T., Wride C.J., White J.H.M., Brown R.;

RT "ElB-19K interacts with a novel apoptotic inducer, NBK.";

RL Submitted (JUL-1995) to the EMBL/GenBank/DBJ databases.

RL [4]

RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].

RX MEDLINE=99431905; PubMed=10500065;

RA Castellani A., Ino Y., Louis D.N., Ramesh V., Gusella J.F., Rustgi A.K.;

RT "Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer.";

RL Gastroenterology 117:831-837(1999).

RL [5]

RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].

RA Kalnine N., Chen X., Rofis A., Halleck A., Hines L., Eisenstein S.,

RA Koundinya M., Raphael J., Moreira D., Kelley T., Labaer J., Lin Y.,

RA Phelan M., Farmer A.;

RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";

| RL | Submitted (OCT-2004) to the EMBL/GenBank/DBJ databases. |

RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX PubMed:15461802; DOI=10.1186/gb-2004-5-10-x84;
RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA Cole C.G., Goward M.E., Aguado B., Mallaya M., Mokrab Y., Huckle E.J.,
RA Beare D.M., Dunham I.;
RT "A genome annotation-driven approach to cloning the human ORFeome.";
RL Genome Biol. 5:RESEARCH84.1-RESEARCH84.11(2004).
[7]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]
RA Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W.,
RA Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robertson P.D.,
RA Schackwitz W.S., Sherwood J.K., Witrak L.A., Nickerson D.A.;
RT "NTEHS-SNPs, environmental genome project, NIEHS ES15478, Department
of Genome Sciences, Seattle, WA [URL: <http://egp.gs.washington.edu>].";
RL Submitted (FEB-2003) to the ENBL/GenBank/DBJ databases.
[8]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX MEDLINE:20057165; PubMed:10591208; DOI=10.1038/990031;
RA Dunham I., Hunt A.R., Collins J.E., Buskiewicz R., Beare D.M.,
RA Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA Baguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA Bird C.P., Blakey S.E., Bridgman A.M., Buck D., Burgess J.,
RA Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA Dhani P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA Gilbert J.G.R., Goward M.E., Grahame D.V., Griffiths M.N.D., Hall C.,
RA Hall R.E., Hall-Tamlyn G., Heathcote R.W., Ho S., Holmes S.,
RA Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA Laird G.K., Langford C.P., Leverhwa M.A., Lloyd C., Lloyd D.M.,
RA Martyn J.D., Mashregheh-Mohammadi M., Matthews L.H., Mccann O.T.,
RA Mcclay J., McLaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA Phillips S.H., Plumb R., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA Soderlund C., Spragon L., Steward C.A., Suleston J.E., Swann R.M.,
RA Vaubin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA Williams L., Williams S.A., Williamson R., Wilmer T.E., Wilming L.,
RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA Minoshima S., Shibasaki K., Saaki T., Asakawa S., Kudoh J.,
RA Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA Lewis J., Lewis S., Lin S.-P., Loh P., Malay E., Nguyen T., Pan H.,
RA Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA Zhan M., Zhang G., Chiesoe S., Murray J., Miller N., Minx P.,
RA Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA Scheet P., Walker C., Wamsley A., Wohlmann P., Pepin K., Nelson J.,
RA Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA Edelman L., Kim U.J., Shitaya H., Simon M.I., Dumaniski J.P.,
RA Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA Khan A.S., Lane L., Tilahun Y., Wright H.;
RT "The DNA sequence of human chromosome 22.";
RL Nature 402:489-495(1999).
[9]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Lymph;
RX MEDLINE:22388257; PubMed:12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshlyuk S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[10]
RP MUTAGENESIS, AND FUNCTION OF BH3 MOTIF.
RX MEDLINE:96091131; PubMed:8521816;
RA Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J.,
RA Elangovan B., Chinnadurai G., Lutz R.J.;
RT "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell
death and protein binding functions.";
RL EMBO J. 14:5589-5596(1995).
CC -!- FUNCTION: Accelerates programmed cell death. Binding to the
CC apoptosis repressors Bcl-X(L), BHRFL, Bcl-2 or its adenovirus
CC homolog E1B 19k protein suppresses this death-promoting activity.
CC Does not interact with BAX.
CC -!- SUBCELLULAR LOCATION: Around the nuclear envelope, and in
CC cytoplasmic membranes.
CC -!- DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX
CC for their pro-apoptotic activity and for their interaction with
CC anti-apoptotic members of the Bcl-2 family.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; U34584; AAC50413.1; -; mRNA.
CC EMBL; U49730; AAC79124.1; -; mRNA.
CC EMBL; X89986; CAA62013.1; -; mRNA.
CC EMBL; AF174424; AAF01156.1; -; Genomic_DNA.
CC EMBL; AF174421; AAF01156.1; JOINED; Genomic_DNA.
CC EMBL; AF174422; AAF01156.1; JOINED; Genomic_DNA.
CC EMBL; AF174423; AAF01156.1; JOINED; Genomic_DNA.
CC EMBL; BT006728; AAP53374.1; -; mRNA.
CC EMBL; CR456390; CAG30276.1; -; mRNA.
CC EMBL; AY245248; AAO61089.1; -; Genomic_DNA.
CC EMBL; AL022237; CAA18260.2; -; Genomic_DNA.
CC EMBL; BC001599; AAH01599.1; -; mRNA.
CC PIR; S58214; S58214.
CC Ensembl; ENSG00000100290; Homo sapiens.
CC HGNC; HGNC:1051; BIK.
CC H-InvDB; HIX0016551; -.
CC MIM; 603392; -.
CC GO; GO:0008632; P:apoptotic program; TAS.
CC GO; GO:0006917; P:induction of apoptosis; TAS.
CC InterPro; IPR00712; Bcl2_BH.
CC PROSITE; PS01259; BH3; 1.
CC TRANSMEM; 136 156
CC Apoptosis; Transmembrane.
CC FT DOMAIN 137 158
CC FT MOTIF 57 71
CC FT CONFLICT 149 150 PL -> LP (in Ref. 1).
CC FT SEQUENCE 160 AA; 18016 MW; 89034443F5A136 CRC64;
CC
CC Query Match 100.0%; Score 809; DB 1; Length 160;
CC Best Local Similarity 100.0%; Pred. No. 8.9e-70;
CC Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
CC
Qy 1 MSEVRPLSRDILMETLYEQLEPPTEVLGMDTSEEDLPMDPFDLSLECGSDALAIR 60
Db 1 MSEVRPLSRDILMETLYEQLEPPTEVLGMDTSEEDLPMDPFDLSLECGSDALAIR 60
Qy 61 LACIGDEMDSLRAPRLAQLSEVAMHSIGLAIFYDQTEDIRDLVRSFMDGFTTLKENIMR 120

Db 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
 QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 2
 ID Q6FH93 HUMAN PRELIMINARY; PRT; 160 AA.
 AC Q6FH93;
 DT 10-MAY-2005 (TREMELrel. 30, Created)
 DT 10-MAY-2005 (TREMELrel. 30, Last sequence update)
 DT 10-MAY-2005 (TREMELrel. 30, Last annotation update)
 DE BIK protein.
 GN Name=BIK;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RA NUCLEOTIDE SEQUENCE.
 RA Halleck A., Ebert L., Moundinya M., Schick M., Eisenstein S.,
 RA Neubert P., Katrang K., Schattten R., Shen B., Henze S., Mar W.,
 RA Korn B., Zuo D., Hu Y., Labaer J.,
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; CR541863; CAG46661.1; -; mRNA.
 DR EMBL; CR541883; CAG46681.1; -; mRNA.
 SQ SEQUENCE 160 AA; 18016 MW; 89034F4443F5A136 CRC64;

Query Match 100.0%; Score 809; DB 2; Length 160;
 Best Local Similarity 100.0%; Pred. No. 8.9e-70;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDIIMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDIIMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 QY 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
 Db 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
 QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 3
 ID Q925D2 RAT PRELIMINARY; PRT; 158 AA.
 AC Q925D2;
 DT 01-DEC-2001 (TREMELrel. 19, Created)
 DT 01-DEC-2001 (TREMELrel. 19, Last sequence update)
 DT 01-DEC-2001 (TREMELrel. 19, Last annotation update)
 DE Bcl2-interacting killer-like protein.
 GN Name=BIKl;
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Rattus.
 OX NCBI_TaxID=101116;
 RN [1]
 RA NUCLEOTIDE SEQUENCE.
 RA STRAIN=Sprague-Dawley;
 RX MEDLINE=22672518; PubMed=12787069;
 RX DOI=10.1046/j.1471-4159.2003.01795.x;
 RA Itoh T., Itoh A., Pleasure D.,
 RA "Bcl-2-related protein family gene expression during oligodendroglial
 RT differentiation."
 RL J. Neurochem. 85:1500-1512(2003).
 DR EMBL; AF372501; AAK53820.1; -; mRNA.

DR Ensembl; ENSRNOG00000010359; Rattus norvegicus.
 DR RGD; 621547; Bklk.
 SQ SEQUENCE 158 AA; 17660 MW; A637425508879C78 CRC64;
 Query Match 37.2%; Score 301; DB 2; Length 158;
 Best Local Similarity 44.3%; Pred. No. 8.4e-21;
 Matches 74; Conservative 29; Mismatches 48; Indels 16; Gaps 7;
 QY 1 MSEVRPLSRDIIMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMG 53
 Db 1 MSEVRPLSRDIIMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMG 55
 QY 54 SDALALRLACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTT 113
 Db 56 RNOVALRLACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTT 112
 QY 114 LKENIMFWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160
 Db 113 LRENIMFWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 158

RESULT 4
 ID Q99L97 MOUSE PRELIMINARY; PRT; 158 AA.
 AC Q99L97;
 DT 01-JUN-2001 (TREMELrel. 17, Created)
 DT 01-JUN-2001 (TREMELrel. 17, Last sequence update)
 DT 01-JUN-2002 (TREMELrel. 21, Last annotation update)
 DE Bklk protein.
 GN Name=Bklk;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RA NUCLEOTIDE SEQUENCE.
 RA STRAIN=CZECH II;
 RC TISSUE=Mammary tumor metastatized to lung. Tumor arose spontaneously;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettner M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences."
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RA NUCLEOTIDE SEQUENCE.
 RA STRAIN=CZECH II;
 RC TISSUE=Mammary tumor metastatized to lung. Tumor arose spontaneously;
 RX Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC003732; AAH03732.1; -; mRNA.
 DR Ensembl; ENSMUSG00000016758; Mus musculus.
 DR MGI; MGI:1206591; Bklk.
 DR GO; GO:0005740; C:mitochondrial membrane; IDA.
 DR GO; GO:0005515; F:protein binding; IPI.
 DR GO; GO:0006917; P:induction of apoptosis; IDA.
 SQ SEQUENCE 158 AA; 17668 MW; D6483418215ABA48 CRC64;


```

DR TIGR; DVUA0065; --
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0001630; F:kinase activity; IEA.
DR GO; GO:0000155; F:two-component sensor molecule activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPRO003594; ATPbind ATPase.
DR InterPro; IPRO005467; His_kinase.
DR InterPro; IPRO003661; His_kinase.
DR InterPro; IPRO004358; His_kin_like_C.
DR Pfam; PF02518; HATPase_c; 1.
DR Pfam; PF00512; HisKA; 1.
DR PRINTS; PR00344; BCTRLSENSOR.
DR SMART; SM00387; HATPase_c; 1.
DR PROSITE; PS0109; HIS_KIN; 1.
DR Complete proteome; Kinase; Plasmid.
KW SEQUENCE 678 AA; 73820 MW; 240FED7865FC3263 CRC64;

Query Match 11.7%; Score 94.5; DB 2; Length 678;
Best Local Similarity 26.9%; Pred. No. 3.8;
Matches 28; Conservative 22; Mismatches 41; Indels 13; Gaps 3;

QY 34 DSEDLDPWEFDLSLECMGSDALALRLACIGDEMVSRLAPRLAQLSEVAMHSL----- 88
Db 431 DTREHD-LEDFELLEAMGRQIALCVSRFLGDELAVAREMEALGRFAALVWHDLNQVY 489

QY 89 GLAFIYD-----QTEDIRVLRSMFGDTTLKENIMRFRWSP 125
Db 490 ALSLLVDNARLYIAEPFQDLVETLTNSVSMRNLISQLTRLP 533

RESULT 8
ID Q7PKI2 ANOGA PRELIMINARY; PRT; 405 AA.
AC Q7PKI2.
DT 01-WAR-2004 (TREMBLrel. 26, Created)
DT 01-WAR-2004 (TREMBLrel. 26, Last sequence update)
DT 01-WAR-2004 (TREMBLrel. 26, Last annotation update)
DE ENSANGP0000024055.
GN ORFNames=ENSANGG000000020093;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Culicidae;
OC Anophelinae; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAAB01008987; EAA43249.1; --; Genomic_DNA.
DR InterPro; IPRO002016; Peroxidase.
DR PROSITE; PS00436; PEROXIDASE_2; UNKNOWN 1.
SQ SEQUENCE 405 AA; 47052 MW; 1B34C60EE72D877C CRC64;

Query Match 10.6%; Score 85.5; DB 2; Length 405;
Best Local Similarity 25.0%; Pred. No. 15;
Matches 29; Conservative 21; Mismatches 35; Indels 31; Gaps 4;

QY 54 SDALALRLACIGDEMVS-----SLRAPRLAQLS-----EVAMHSLGLAFIYDQTEIRDLV 104
Db 45 SHALATLLLCVYPVVVILLTGIRPKLTIVNVLVWMCQSLHYVNLALIVYHLLPARPVI 104

QY 105 RSPMDGFTTL-----KENIMRFRWSPNPGSWVSCQVLLALLL 143
Db 105 RNIFNGFVQLFRTLNGAGCHRWKGTCKKNVLK-----ALKMILCDTLTLCALFVL 155

RESULT 9

```

```

Q4WGN9 ASPFU PRELIMINARY; PRT; 2004 AA.
ID Q4WGN9;
AC Q4WGN9;
DT 13-SEP-2005 (TREMBLrel. 31, Created)
DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)
DE Guany1-nucleotide exchange factor (Sec7), putative.
GN ORFNames=Afu7G05700;
OS Aspergillus fumigatus Af293.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
OX NCBI_TaxID=330879;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Af293;
RA Nierman W., Pain A., Anderson M.J., Wortman J., Kim H., Stanley.,
RA Arroya J., Berriman M., Abe K., Archer D.B., Bermejo C., Bennett J.,
RA Bowyer P., Chen D., Collins M., Coulson R., Davies R., Dyer P.S.,
RA Farman M., Fedorova N., Fedorova N., Feldblyum T.V., Fischer R.,
RA Foster N., Fraser A., Garcia J.L., Garcia M.J., Goble A.,
RA Goldman G.H., Goni K., Griffith-Jones S., Gwilliam R., Haas B.,
RA Haas H., Harris D., Horiuchi H., Huang J., Humphrey S., Jimenez J.,
RA Keller N., Khouri H., Kitamoto K., Kobayashi T., Kulkarni R.,
RA Kumagai T., Lafton A., Latge J.-P., Li W., Lord A., Lu C.,
RA Majoros W.H., May G.S., Miller B.L., Mohamoud Y., Molina M., Monod M.,
RA Mouyna I., Mulligan S., Murphy L., O'Neil S., Paulsen I.,
RA Penalva M.A., Pertea M., Price C., Pritchard B.L., Quail M.A.,
RA Rabinowitsch E., Rawlins N., Rajandream M.-A., Reichard U.,
RA Renauld H., Robson G.D., Rodriguez de Cordoba S., Rodriguez-Pena J.M.,
RA Ronning C.M., Rutter S., Salzberg S.L., Sanchez M.,
RA Sanchez-Ferrero J.C., Saunders D., Seeger K., Squares R., Squares S.,
RA Takeuchi M., Tekala F., Turner G., Vazquez de Aldana C.R., Weidman J.,
RA White O., Woodward J., Yu J.-H., Fraser C., Galagan J.E., Asai K.,
RA Machida M., Hall N., Barrell B., Denning D.W.;
RT "Genomic sequence of the pathogenic and allergenic filamentous fungus
ASpergillus fumigatus.";
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAHF01000009; EAL86902.1; --; Genomic DNA.
SQ SEQUENCE 2004 AA; 225549 MW; 985CE30E0BA92457 CRC64;

Query Match 10.5%; Score 85; DB 2; Length 2004;
Best Local Similarity 29.0%; Pred. No. 1.1e+02;
Matches 31; Conservative 19; Mismatches 41; Indels 16; Gaps 5;

QY 41 PMEDFDSLE----CMGSDALALRLACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQ 96
Db 1093 PMQDTQNLETTIKLCMEGM-KLAIRISCAFD-----LETPRVAFVTGLAKFT-NLGNVREM 1145

QY 97 TEDIRDVLRSMFGDTTLKENIMRFRWSPNPGSWVSCQVLLALLL 143
Db 1146 VPKNVKALKALDVALTEGNNLKSSWREV-----LTCVSQDLRLQLL 1187

RESULT 10
ID Q70C70 STRTR PRELIMINARY; PRT; 705 AA.
AC Q70C70;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE Cadmium efflux ATPase.
GN Name=cadA;
OS Streptococcus thermophilus.
OC Bacteria; Firmicutes; Lactobacillales; Streptococcaceae;
OC Streptococcus.
OX NCBI_TaxID=1308;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=CNR2308;
RA Pavlovic G., Burrus V., Gintz B., Decaris B., Guedon G.;

```


155 I S P T E A F O T O V T S S S N N I . E I K O M E R V P I . T E F S K D V L E D I T E E S E R L L S M S T T

Db 160 EEKLRDIIIPETLFI-----PRTPAPGNTDVRDFINERLKEHDLDPAPPYDSLATY

Qv 51 MEGSDALALRLACI-----GDEMVDVSLR--APRLAQLSEV 83

155 I S P T E A F O T O V T S S S N N I . E I K O M E R V P I . T E F S K D V L E D I T E E S E R L L S M S T T

Job time : 232 secs

THIS PAGE BLANK (USPTO)

This Page Blank (uspto)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2006, 19:13:04 ; Search time 47 Seconds
(without alignments)
281.449 Million cell updates/sec

Title: US-10-816-698-3
Perfect score: 809
Sequence: 1 MSEVRLSRDILMETLLYEQ.....LLLLALLPLLSGGHLHLK 160

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/1aa/5 COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/6 COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/H COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/PTUS COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/RE COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	809	100.0	160	1	US-08-408-095-27
2	809	100.0	160	2	US-09-052-877-5
3	809	100.0	160	2	US-09-709-790-5
4	472	58.3	99	2	US-09-513-999C-7729
5	284	35.1	150	2	US-09-052-877-2
6	284	35.1	150	2	US-09-709-790-2
7	177	21.9	36	1	US-08-440-391-12
8	177	21.9	36	1	US-08-908-597A-12
9	177	21.9	36	2	US-09-236-385A-12
10	177	21.9	36	4	PCT-US96-06122-12
11	142	17.6	28	1	US-08-440-391-30
12	142	17.6	28	1	US-08-908-597A-30
13	142	17.6	28	2	US-09-236-385A-30
14	142	17.6	28	4	PCT-US96-06122-30
15	138	17.1	27	2	US-09-544-664B-16
16	135	16.7	28	1	US-08-440-391-9
17	135	16.7	28	1	US-08-908-597A-9
18	135	16.7	28	2	US-09-236-385A-9
19	135	16.7	28	4	PCT-US96-06122-9
20	98	12.1	20	2	US-09-236-385A-41
21	92	11.4	15	1	US-08-632-514C-15
22	92	11.4	15	2	US-09-188-177-15
23	81.5	10.1	392	1	US-08-282-197C-60
24	80	9.9	16	2	US-09-544-664B-43
25	77	9.5	1198	2	US-09-252-991A-21016
26	75.5	9.3	414	1	US-08-845-161A-2
27	75.5	9.3	414	2	US-09-270-751-2

28	75.5	9.3	414	2	US-09-168-218B-4	Sequence 4, Appli
29	75	9.3	320	2	US-08-852-730-9	Sequence 9, Appli
30	75	9.3	340	2	US-09-722-441-10	Sequence 10, Appli
31	74	9.1	15	1	US-08-440-391-7	Sequence 7, Appli
32	74	9.1	15	1	US-08-440-391-32	Sequence 32, Appli
33	74	9.1	15	1	US-08-908-597A-7	Sequence 7, Appli
34	74	9.1	15	1	US-08-908-597A-32	Sequence 32, Appli
35	74	9.1	15	2	US-09-236-385A-7	Sequence 7, Appli
36	74	9.1	15	2	US-09-236-385A-32	Sequence 32, Appli
37	74	9.1	15	4	PCT-US96-06122-7	Sequence 7, Appli
38	74	9.1	15	4	PCT-US96-06122-32	Sequence 32, Appli
39	74	9.1	330	2	US-09-725-957-18	Sequence 18, Appli
40	74	9.1	389	2	US-08-909-828-3	Sequence 3, Appli
41	74	9.1	389	2	US-09-725-957-3	Sequence 3, Appli
42	74	9.1	389	2	US-09-725-957-14	Sequence 14, Appli
43	73.5	9.1	877	1	US-08-916-917-2	Sequence 2, Appli
44	73.5	9.1	877	1	US-08-972-631-2	Sequence 2, Appli
45	73.5	9.1	877	1	US-08-972-629-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-08-408-095-27
; Sequence 27, Application US/08408095
; Patent No. 5858678
; GENERAL INFORMATION:
; APPLICANT: Chinnadurai, Govindaswamy
; TITLE OF INVENTION: APOPTOSIS-REGULATING PROTEINS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
; STREET: 2100 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/408,095
; FILING DATE: 21-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Mack, Susan J.
; REGISTRATION NUMBER: 30,951
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)293-7060
; TELEFAX: (202)293-7860
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 160 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-408-095-27

Query Match 100.0%; Score 809; DB 1; Length 160;
Best Local Similarity 100.0%; Pred. No. 4.9e-92;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MSEVRLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLCMEGSDALALR	60
DB	1	MSEVRLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLCMEGSDALALR	60
QY	61	LACIGDMDVSLRAPRLAQLSEVAMHSLGLAFIYDQTDIRDVLRSFMDGFTTLKENIMR	120
DB	61	LACIGDMDVSLRAPRLAQLSEVAMHSLGLAFIYDQTDIRDVLRSFMDGFTTLKENIMR	120

Qy 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 2

US-09-052-877-5
; Sequence 5, Application US/09052877
; Patent No. 6190912
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES
; THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/052,877
; FILING DATE: 31-MAR-1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 480140.433
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 160 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; US-09-052-877-5

Query Match 100.0%; Score 809; DB 2; Length 160;
Best Local Similarity 100.0%; Pred. No. 4.9e-92;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 3

US-09-709-790-5
; Sequence 5, Application US/09709790
; Patent No. 6600024
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES
; THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP

; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/709,790
; FILING DATE: 07-No. 6600024-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/052,877
; FILING DATE: 31-MAR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 480140.433
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 160 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
; US-09-709-790-5

Query Match 100.0%; Score 809; DB 2; Length 160;
Best Local Similarity 100.0%; Pred. No. 4.9e-92;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 4

US-09-513-999C-7729
; Sequence 7729, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Ducielt, A.
; APPLICANT: Dumas Milne Edwards, J.B.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
; FILE REFERENCE: 59, US2, REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 7729
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: UNSURE

```

; LOCATION: 66
; OTHER INFORMATION: Xaa=Leu or Met or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 86
; OTHER INFORMATION: Xaa=Ala or Asp or Gly or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 99
; OTHER INFORMATION: Xaa=Ala or Glu
; US-09-513-999C-7729

Query Match      58.3%; Score 472; DB 2; Length 99;
Best Local Similarity 96.9%; Pred. No. 1.4e-50;
Matches 93; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 20 QLLPPTMEVLGMDTSEEDLPDMEDFDSLECMGSDALALRLACIGDMVSLRAPLQAQ 79
Db 3 RLLEPPTMEVLGMDTSEEDLPDMEDFDSLECMGSDALALRLACIGDMVSLRAPLQAQ 62

Qy 80 LSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLK 115
Db 63 LSEXAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLK 98

RESULT 5
US-09-052-877-2
; Sequence 2, Application US/09052877
; Patent No. 6190912
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES
; THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 31-MAR-1998
; CLASSIFICATION: 514
; APPLICATION NUMBER: US/09/052,877
; PRIORITY/DOCKET NUMBER: 480140.433
; TELECOMMUNICATION INFORMATION:
; NAME: Maki, David J.
; REFERENCE/DOCKET NUMBER: 31,392
; REGISTRATION NUMBER: 480140.433
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 622-4900
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 150 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-052-877-2

Query Match      35.1%; Score 284; DB 2; Length 150;
Best Local Similarity 42.5%; Pred. No. 5e-27;
Matches 68; Conservative 33; Mismatches 49; Indels 10; Gaps 6;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLPDMEDFDSLECMGSDALALR 60
Db 1 MSEARLMARDVI-KTYPHQVQPP---VASETPSMK--EPVRDVLMECVGRNQVALR 54

Qy 61 LACIGDEMVSRLRAPLQAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 55 LACIGDEMVDLCLRSPLVQLPGIAIHR--LAVTYSRT-GVRCIFRSLRSLNLRNINWS 111

Qy 121 FWRSPNPGSWVSCQVLLALALLLALLPLLSGGHLHLK 160
Db 112 -WRVLTGAWVSPDQPGQLPFMVLVLLFLLGGAWYLQIQ 150

Query Match      35.1%; Score 284; DB 2; Length 150;
Best Local Similarity 42.5%; Pred. No. 5e-27;
Matches 68; Conservative 33; Mismatches 49; Indels 10; Gaps 6;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLPDMEDFDSLECMGSDALALR 60
Db 1 MSEARLMARDVI-KTYPHQVQPP---VASETPSMK--EPVRDVLMECVGRNQVALR 54

Qy 61 LACIGDEMVSRLRAPLQAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 55 LACIGDEMVDLCLRSPLVQLPGIAIHR--LAVTYSRT-GVRCIFRSLRSLNLRNINWS 111

Qy 121 FWRSPNPGSWVSCQVLLALALLLALLPLLSGGHLHLK 160
Db 112 -WRVLTGAWVSPDQPGQLPFMVLVLLFLLGGAWYLQIQ 150

RESULT 7
US-08-440-391-12
; Sequence 12, Application US/08440391

```

```

Qy 61 LACIGDEMVSRLRAPLQAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 55 LACIGDEMVDLCLRSPLVQLPGIAIHR--LAVTYSRT-GVRCIFRSLRSLNLRNINWS 111

Qy 121 FWRSPNPGSWVSCQVLLALALLLALLPLLSGGHLHLK 160
Db 112 -WRVLTGAWVSPDQPGQLPFMVLVLLFLLGGAWYLQIQ 150

RESULT 6
US-09-709-790-2
; Sequence 2, Application US/09709790
; Patent No. 6600024
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES
; THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/709,790
; FILING DATE: 07-NOV-2000
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/052,877
; FILING DATE: 31-MAR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 480140.433
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 150 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-709-790-2

Query Match      35.1%; Score 284; DB 2; Length 150;
Best Local Similarity 42.5%; Pred. No. 5e-27;
Matches 68; Conservative 33; Mismatches 49; Indels 10; Gaps 6;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLPDMEDFDSLECMGSDALALR 60
Db 1 MSEARLMARDVI-KTYPHQVQPP---VASETPSMK--EPVRDVLMECVGRNQVALR 54

Qy 61 LACIGDEMVSRLRAPLQAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 55 LACIGDEMVDLCLRSPLVQLPGIAIHR--LAVTYSRT-GVRCIFRSLRSLNLRNINWS 111

Qy 121 FWRSPNPGSWVSCQVLLALALLLALLPLLSGGHLHLK 160
Db 112 -WRVLTGAWVSPDQPGQLPFMVLVLLFLLGGAWYLQIQ 150

RESULT 7
US-08-440-391-12
; Sequence 12, Application US/08440391

```

```

; Patent No. 5656725
; GENERAL INFORMATION:
; APPLICANT: CHITTENDEN, Thomas D.; and
; APPLICANT: LUTZ, Robert J.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
; MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,391
; FILING DATE: 12-MAY-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; REFERENCE/DOCKET NUMBER: 104322.147
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-440-391-12

```

```

Query Match 21.9%; Score 177; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 48 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 83
Db 1 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 36

```

```

RESULT 8
US-08-908-597A-12
; Sequence 12, Application US/08908597A
; Patent No. 5863795
; GENERAL INFORMATION:
; APPLICANT: CHITTENDEN, Thomas D.; and
; APPLICANT: LUTZ, Robert J.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
; MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/908,597A
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,391

```

```

; FILING DATE: 12-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; REFERENCE/DOCKET NUMBER: 104322.147
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-908-597A-12

```

```

Query Match 21.9%; Score 177; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 48 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 83
Db 1 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 36

```

```

RESULT 9
US-09-236-385A-12
; Sequence 12, Application US/09236385A
; Patent No. 6221615
; GENERAL INFORMATION:
; APPLICANT: CHITTENDEN, Thomas D.; and
; APPLICANT: LUTZ, Robert J.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
; MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/236,385A
; FILING DATE: 25-Jan-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-236-385A-12

```

```

Query Match 21.9%; Score 177; DB 2; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 48 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 83
Db 1 LECMEGSDALALRLACIGDEMVDVSLRAPRLAQLSEV 36

```

RESULT 10
PCT-US96-06122-12
; Sequence 12, Application PC/TUS9606122
; GENERAL INFORMATION:
APPLICANT: IMMUNOGEN, INC.
TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS
TITLE OF INVENTION: WHICH MODULATE APOPTOSIS
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSER: Hale and Dorr
STREET: 1455 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/06122
FILING DATE: 12-MAY-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/440,391
FILING DATE: 12-MAY-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: WIXON, HENRY N.
REGISTRATION NUMBER: 32,073
REFERENCE/DOCKET NUMBER: 104322.147PCT
TELEPHONE: 202-942-8400
TELEFAX: 202-942-8484
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
PCT-US96-06122-12

Query Match 21.9%; Score 177; DB 4; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 LECMGSDALALRLACIGDEMVDVSLRAPLQISEV 83
|||||
DB 1 LECMGSDALALRLACIGDEMVDVSLRAPLQISEV 36

RESULT 11
US-08-440-391-30
; Sequence 30, Application US/08440391
; Patent No. 5656725
; GENERAL INFORMATION:
APPLICANT: CHITTENDEN, Thomas D.; and
APPLICANT: LUTZ, Robert J.
TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
MODULATE APOPTOSIS
TITLE OF INVENTION: MODULATE APOPTOSIS
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSER: Hale and Dorr
STREET: 1455 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/440,391
FILING DATE: 12-MAY-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: WIXON, HENRY N.
REGISTRATION NUMBER: 32,073
REFERENCE/DOCKET NUMBER: 104322.147
TELEPHONE: 202-942-8400
TELEFAX: 202-942-8484
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 28 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-440-391-30

Query Match 17.6%; Score 142; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.7e-10;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 CMEGSDALALRLACIGDEMVDVSLRAPRL 77
|||||
DB 1 CMEGSDALALRLACIGDEMVDVSLRAPRL 28

RESULT 12
US-08-908-597A-30
; Sequence 30, Application US/08908597A
; Patent No. 5863795
; GENERAL INFORMATION:
APPLICANT: CHITTENDEN, Thomas D.; and
APPLICANT: LUTZ, Robert J.
TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
MODULATE APOPTOSIS
TITLE OF INVENTION: MODULATE APOPTOSIS
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSER: Hale and Dorr
STREET: 1455 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/908,597A
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/440,391
FILING DATE: 12-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: WIXON, HENRY N.
REGISTRATION NUMBER: 32,073
REFERENCE/DOCKET NUMBER: 104322.147
TELEPHONE: 202-942-8400
TELEFAX: 202-942-8484
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 28 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-908-597A-30

Query Match 17.6%; Score 142; DB 1; Length 28;

Best Local Similarity 100.0%; Pred. No. 1.7e-10;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 CMEGSDALALRLACIGDEMDVSLRAPRL 77
Db 1 CMEGSDALALRLACIGDEMDVSLRAPRL 28

RESULT 13
US-09-236-385A-30
; Sequence 30, Application US/09236385A
; Patent No. 6221615
; GENERAL INFORMATION:
; APPLICANT: CHITTENDEN, Thomas D.; and
; LUTZ, Robert J.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
; MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/236,385A
; FILING DATE: 25-Jan-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-09-236-385A-30

Query Match 17.6%; Score 142; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.7e-10;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 CMEGSDALALRLACIGDEMDVSLRAPRL 77
Db 1 CMEGSDALALRLACIGDEMDVSLRAPRL 28

RESULT 14
PCT-US96-06122-30
; Sequence 30, Application PC/TUS9606122
; GENERAL INFORMATION:
; APPLICANT: IMMUNOGEN, INC.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS
; WHICH MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/06122
; FILING DATE: HEREWITH
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/440,391
; FILING DATE: 12-MAY-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; REFERENCE/DOCKET NUMBER: 104322.147PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US96-06122-30

Query Match 17.6%; Score 142; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.7e-10;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 CMEGSDALALRLACIGDEMDVSLRAPRL 77
Db 1 CMEGSDALALRLACIGDEMDVSLRAPRL 28

RESULT 15
US-09-544-664B-16
; Sequence 16, Application US/09544664B
; Patent No. 6713280
; GENERAL INFORMATION:
; APPLICANT: Huang, Ziwei
; APPLICANT: Wang, Jialun
; APPLICANT: Zhang, Zhijia
; APPLICANT: Shan, Simel
; APPLICANT: Lu, Zhixian
; TITLE OF INVENTION: Enhancement of Peptide Cellular Uptake
; FILE REFERENCE: 8321-68
; CURRENT APPLICATION NUMBER: US/09/544,664B
; CURRENT FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: PCT/US00/09352
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 60/128,202
; PRIOR FILING DATE: 1999-04-07
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 27
; TYPE: PPT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide
; OTHER INFORMATION: segment from BH3 domain of a Bcl-2 superfamily
; OTHER INFORMATION: polypeptide
US-09-544-664B-16

Query Match 17.1%; Score 138; DB 2; Length 27;
Best Local Similarity 100.0%; Pred. No. 5.1e-10;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 CMEGSDALALRLACIGDEMDVSLRAPR 76
Db 1 CMEGSDALALRLACIGDEMDVSLRAPR 27

Search completed: March 15, 2006, 19:14:26
Job time : 48 secs

THIS PAGE BLANK (USPTO)

This Page Blank (uspto)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2006, 19:13:49 ; Search time 167 Seconds
(without alignments)
400.316 Million cell updates/sec

Title: US-10-816-698-3

Perfect score: 809

Sequence: 1 MSEVRPLSRDILMETLLYEQ.....LLLLALLPLSGGLHLK 160

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main:

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	809	100.0	160	4	US-10-269-781-5
2	809	100.0	160	4	US-10-295-027-1373
3	809	100.0	160	4	US-10-003-632C-8
4	809	100.0	160	5	US-10-825-282-30
5	809	100.0	160	5	US-10-816-698-3
6	809	100.0	175	4	US-10-106-698-4857
7	809	100.0	175	4	US-10-264-049-2649
8	805	99.5	160	5	US-10-816-698-8
9	803	99.3	160	5	US-10-816-698-7
10	799	98.8	160	5	US-10-816-698-9
11	284	35.1	150	4	US-10-269-781-2
12	284	35.1	150	5	US-10-816-698-4
13	214	26.5	44	3	US-09-971-980-43
14	214	26.5	44	5	US-10-966-576-43
15	177	21.9	36	3	US-09-828-870-12
16	143	17.7	27	4	US-10-029-386-30479
17	142	17.6	28	3	US-09-828-870-30
18	135	16.7	28	3	US-09-828-870-9
19	135	16.7	61	3	US-09-925-299-1062
20	135	16.7	61	3	US-09-925-299-1062
21	135	16.7	61	4	US-10-106-698-6558
22	122	15.1	27	5	US-10-816-698-14
23	100	12.4	20	4	US-10-658-028A-5
24	98	12.1	20	3	US-09-828-870-41
25	87	10.8	18	5	US-10-816-698-12
26	87	10.8	18	5	US-10-816-698-13
27	85	10.5	204	4	US-10-424-599-172616

28	85	10.5	1908	4	US-10-128-714-3475	Sequence 3475, Ap
29	85	10.5	2022	4	US-10-128-714-8475	Sequence 8475, Ap
30	84.5	10.4	753	4	US-10-369-493-20200	Sequence 20200, A
31	84.5	10.4	775	5	US-10-732-923-12744	Sequence 12744, A
32	84	10.4	1120	6	US-11-097-143-31380	Sequence 31380, A
33	82.5	10.2	964	4	US-10-042-865-55	Sequence 55, Appl
34	82.5	10.2	1045	4	US-10-042-865-54	Sequence 54, Appl
35	82.5	10.2	1045	4	US-10-029-020-54	Sequence 54, Appl
36	82.5	10.2	1769	5	US-10-723-860-4494	Sequence 4494, Ap
37	82.5	10.2	2346	4	US-10-072-012-491	Sequence 491, App
38	82.5	10.2	2613	4	US-10-038-854-42	Sequence 42, Appl
39	82.5	10.2	2628	4	US-10-038-854-40	Sequence 40, Appl
40	82.5	10.2	2715	4	US-10-042-865-52	Sequence 52, Appl
41	82.5	10.2	2715	4	US-10-029-020-51	Sequence 51, Appl
42	82.5	10.2	2721	4	US-10-038-854-38	Sequence 38, Appl
43	82.5	10.2	2725	4	US-10-038-854-36	Sequence 36, Appl
44	79	9.8	906	4	US-10-437-963-128708	Sequence 128708,
45	78.5	9.7	371	4	US-10-425-114-56563	Sequence 56563, A

ALIGNMENTS

RESULT 1
US-10-269-781-5
; Sequence 5, Application US/10269781
; Publication No. US20030060416A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/269,781
; FILING DATE: 11-Oct-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/052,877
; FILING DATE: 31-MAR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
; REFERENCE/DOCKET NUMBER: 480140.433
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 160 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-269-781-5

Query Match 100.0%; Score 809; DB 4; Length 160;
Best Local Similarity 100.0%; Pred. No. 3.6e-79;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSIEDLPMDPDLSCMGSGDALAUR 60
|||||

Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
 Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 2

US-10-295-027-1373
 ; Sequence 1373, Application US/10295027
 ; Publication No. US2003023350A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Afar, Daniel
 ; APPLICANT: Aziz, Natasha
 ; APPLICANT: Gineberg, Wendy M.
 ; APPLICANT: Gish, Kurt C.
 ; APPLICANT: Glynn, Richard
 ; APPLICANT: Hevezi, Peter A.
 ; APPLICANT: Mack, David H.
 ; APPLICANT: Murray, Richard
 ; APPLICANT: Watson, Susan R.
 ; APPLICANT: Eos Biotechnology, Inc.
 ; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
 ; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer
 ; FILE REFERENCE: 018501-012500US
 ; CURRENT APPLICATION NUMBER: US/10/295,027
 ; CURRENT FILING DATE: 2002-11-13
 ; PRIOR APPLICATION NUMBER: US 09/663,733
 ; PRIOR FILING DATE: 2000-09-15
 ; PRIOR APPLICATION NUMBER: US 60/350,666
 ; PRIOR FILING DATE: 2001-11-13
 ; PRIOR APPLICATION NUMBER: US 60/335,394
 ; PRIOR FILING DATE: 2001-11-15
 ; PRIOR APPLICATION NUMBER: US 60/332,464
 ; PRIOR FILING DATE: 2001-11-21
 ; PRIOR APPLICATION NUMBER: US 60/334,393
 ; PRIOR FILING DATE: 2001-11-29
 ; PRIOR APPLICATION NUMBER: US 60/340,376
 ; PRIOR FILING DATE: 2001-12-14
 ; PRIOR APPLICATION NUMBER: US 60/347,211
 ; PRIOR FILING DATE: 2002-01-08
 ; PRIOR APPLICATION NUMBER: US 60/347,349
 ; PRIOR FILING DATE: 2002-01-10
 ; PRIOR APPLICATION NUMBER: US 60/355,250
 ; PRIOR FILING DATE: 2002-02-08
 ; PRIOR APPLICATION NUMBER: US 60/356,714
 ; PRIOR FILING DATE: 2002-02-13
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 1386
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 1373
 ; LENGTH: 160
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-295-027-1373

Query Match 100.0%; Score 809; DB 4; Length 160;
 Best Local Similarity 100.0%; Pred. No. 3.6e-79;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
 Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 3

US-10-003-632C-8
 ; Sequence 8, Application US/10003632C
 ; Publication No. US20040043028A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Lee, Chichang; Ly, Celia; Moore, Gordon; Chi, Xianmei
 ; TITLE OF INVENTION: Methods and Compositions for Enhanced Protein Expression and/or G
 ; TITLE OF INVENTION: Cultured Cells Using Co-Transcription of a Bcl2 Encoding Nucleic
 ; FILE REFERENCE: CEN0269
 ; CURRENT APPLICATION NUMBER: US/10/003,632C
 ; CURRENT FILING DATE: 2001-11-02
 ; NUMBER OF SEQ ID NOS: 14
 ; SOFTWARE: PatentIn Ver 3.1
 ; SEQ ID NO 8
 ; LENGTH: 160
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-003-632C-8

Query Match 100.0%; Score 809; DB 4; Length 160;
 Best Local Similarity 100.0%; Pred. No. 3.6e-79;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDLDPMEDFDSLECMGSDALALR 60
 Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
 Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 4

US-10-825-282-30
 ; Sequence 30, Application US/10825282
 ; Publication No. US20040224389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: 3921-1-1-1
 ; TITLE OF INVENTION: VIRAL VECTORS ENCODING APOPTOSIS-INDUCING PROTEINS AND
 ; TITLE OF INVENTION: METHODS FOR MAKING AND USING THE SAME
 ; FILE REFERENCE: 3921-1-1-1
 ; CURRENT APPLICATION NUMBER: US/10/825,282
 ; CURRENT FILING DATE: 2004-04-14
 ; PRIOR APPLICATION NUMBER: US/09/456,357
 ; PRIOR FILING DATE: 1999-12-08
 ; PRIOR APPLICATION NUMBER: 60/134,416
 ; PRIOR FILING DATE: 1999-05-17
 ; PRIOR APPLICATION NUMBER: 09/087,195
 ; PRIOR FILING DATE: 1998-05-29
 ; PRIOR APPLICATION NUMBER: 08/378,507
 ; PRIOR FILING DATE: 1995-01-26
 ; PRIOR APPLICATION NUMBER: 08/250,478
 ; PRIOR FILING DATE: 1994-05-27
 ; NUMBER OF SEQ ID NOS: 50
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 30
 ; LENGTH: 160
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-825-282-30

Query Match 100.0%; Score 809; DB 5; Length 160;
 Best Local Similarity 100.0%; Pred. No. 3.6e-79;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
DB 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
QY 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
DB 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 5

US-10-816-698-3
; Sequence 3, Application US/10816698
; Publication No. US20050118154A1
; GENERAL INFORMATION:
; APPLICANT: HUNG, MIEN-CHIE
; APPLICANT: LI, YAN
; APPLICANT: WEN, YONG
; TITLE OF INVENTION: ANTITUMOR EFFECT OF MUTANT BIK
; FILE REFERENCE: UTSC:791US
; CURRENT APPLICATION NUMBER: US/10/816,698
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: 60/459,901
; PRIOR FILING DATE: 2003-04-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-816-698-3

Query Match 100.0%; Score 809; DB 5; Length 160;
Best Local Similarity 100.0%; Pred. No. 3.6e-79;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
DB 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
QY 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
DB 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160

RESULT 6

US-10-106-698-4857
; Sequence 4857, Application US/10106698
; Publication No. US20030109690A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Colon and Colon Cancer Associated Polynucleotides and Polypeptide
; FILE REFERENCE: PA005P1
; CURRENT APPLICATION NUMBER: US/10/106,698
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: PCT/US00/26524
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/157,137
; PRIOR FILING DATE: 1999-09-29
; PRIOR APPLICATION NUMBER: US 60/163,280
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 8564
; SOFTWARE: PatentIn Ver. 3.0

; SEQ ID NO 4857
; LENGTH: 175
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-106-698-4857

Query Match 100.0%; Score 809; DB 4; Length 175;
Best Local Similarity 100.0%; Pred. No. 4e-79;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
DB 16 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 75
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 76 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 135
QY 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
DB 136 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 175

RESULT 7

US-10-264-049-2649
; Sequence 2649, Application US/10264049
; Publication No. US20040005579A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA133P1
; CURRENT APPLICATION NUMBER: US/10/264,049
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/18569
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: US 60/209,467
; PRIOR FILING DATE: 2000-06-07
; NUMBER OF SEQ ID NOS: 4360
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 2649
; LENGTH: 175
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-264-049-2649

Query Match 100.0%; Score 809; DB 4; Length 175;
Best Local Similarity 100.0%; Pred. No. 4e-79;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 60
DB 16 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDSSEEDLDPMEDFDSLECMGSDALALR 75
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 76 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 135
QY 121 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 160
DB 136 FWRSPNPGSWSCQVLLALLLALLLPLLSGGHLHLK 175

RESULT 8

US-10-816-698-8
; Sequence 8, Application US/10816698
; Publication No. US20050118154A1
; GENERAL INFORMATION:
; APPLICANT: HUNG, MIEN-CHIE
; APPLICANT: LI, YAN
; APPLICANT: WEN, YONG
; TITLE OF INVENTION: ANTITUMOR EFFECT OF MUTANT BIK
; FILE REFERENCE: UTSC:791US
; CURRENT APPLICATION NUMBER: US/10/816,698

```
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: 60/459,901
; PRIOR FILING DATE: 2003-04-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-816-698-8

Query Match          99.5%; Score 805; DB 5; Length 160;
Best Local Similarity 99.4%; Pred. No. 9.8e-79;
Matches 159; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Qy 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160

RESULT 9
US-10-816-698-7
; Sequence 7, Application US/10816698
; Publication No. US20050118154A1
; GENERAL INFORMATION:
; APPLICANT: HUNG, MIEN-CHIE
; APPLICANT: LI, YAN
; APPLICANT: WEN, YONG
; TITLE OF INVENTION: ANTITUMOR EFFECT OF MUTANT BIK
; FILE REFERENCE: UTSC:791US
; CURRENT APPLICATION NUMBER: US/10/816,698
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: 60/459,901
; PRIOR FILING DATE: 2003-04-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-816-698-7

Query Match          99.3%; Score 803; DB 5; Length 160;
Best Local Similarity 99.4%; Pred. No. 1.6e-78;
Matches 159; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Qy 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160
```

```
RESULT 10
US-10-816-698-9
; Sequence 9, Application US/10816698
; Publication No. US20050118154A1
; GENERAL INFORMATION:
; APPLICANT: HUNG, MIEN-CHIE
; APPLICANT: LI, YAN
; APPLICANT: WEN, YONG
; TITLE OF INVENTION: ANTITUMOR EFFECT OF MUTANT BIK
; FILE REFERENCE: UTSC:791US
; CURRENT APPLICATION NUMBER: US/10/816,698
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: 60/459,901
; PRIOR FILING DATE: 2003-04-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-816-698-9

Query Match          98.8%; Score 799; DB 5; Length 160;
Best Local Similarity 98.8%; Pred. No. 4.4e-78;
Matches 158; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGMDTSEEDLDPMEDFDSLECMEGSDALALR 60
Qy 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160
Db 121 FWRSPNPGSWSCQVLLALLLALLLALLLPLLSSGGLHLHLK 160

RESULT 11
US-10-269-781-2
; Sequence 2, Application US/10269781
; Publication No. US20030060416A1
; GENERAL INFORMATION:
; APPLICANT: Alnemri, Emad S.
; TITLE OF INVENTION: BLK GENES, GENE PRODUCTS AND USES
; THEREOF IN APOPTOSIS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/269,781
; FILING DATE: 11-Oct-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/052,877
; FILING DATE: 31-MAR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Maki, David J.
; REGISTRATION NUMBER: 31,392
```

REFERENCE/DOCKET NUMBER: 480140.433
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 150 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-269-781-2

Query Match 35.1%; Score 284; DB 4; Length 150;
Best Local Similarity 42.5%; Pred. No. 2.1e-22;
Matches 68; Conservative 33; Mismatches 49; Indels 10; Gaps 6;

QY 1 MSEVRPLSRDILMETLLYEQLLEPPPTMEVLGMDTSEEDLPDMEFDSLECMGSDALALR 60
DB 1 MSEARLMARDVI-KTVPHDQVPQP---VASETPSMK--EPVRDVLMECVGRNQVALR 54

QY 61 LACIGDEMDSVLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
DB 55 LACIGDEMDCILRSRLVQLPGIAIHR--LAVTYSRT-GVRGIFRSLRSLTNLRENIWS 111

QY 121 FWRSPNPGSWVSCQVLLALLLALLLALLPLLSGGLHLHLK 160
DB 112 -WRVLTPGAWSVDQDQPGQLFPMVLLVFLLLGGAWYLQLQ 150

RESULT 12
US-10-816-698-4
; Sequence 4, Application US/10816698
; Publication No. US20050118154A1
; GENERAL INFORMATION:
; APPLICANT: HUNG, MIEN-CHIE
; APPLICANT: LI, YAN
; APPLICANT: WEN, YONG
; TITLE OF INVENTION: ANTI-TUMOR EFFECT OF MUTANT BIK
; FILE REFERENCE: UTSC:791US
; CURRENT APPLICATION NUMBER: US/10/816,698
; CURRENT FILING DATE: 2004-04-02
; PRIOR APPLICATION NUMBER: 60/459,901
; PRIOR FILING DATE: 2003-04-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 150
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Peptide
US-10-816-698-4

Query Match 35.1%; Score 284; DB 5; Length 150;
Best Local Similarity 42.5%; Pred. No. 2.1e-22;
Matches 68; Conservative 33; Mismatches 49; Indels 10; Gaps 6;

QY 1 MSEVRPLSRDILMETLLYEQLLEPPPTMEVLGMDTSEEDLPDMEFDSLECMGSDALALR 60
DB 1 MSEARLMARDVI-KTVPHDQVPQP---VASETPSMK--EPVRDVLMECVGRNQVALR 54

QY 61 LACIGDEMDSVLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
DB 55 LACIGDEMDCILRSRLVQLPGIAIHR--LAVTYSRT-GVRGIFRSLRSLTNLRENIWS 111

QY 121 FWRSPNPGSWVSCQVLLALLLALLLALLPLLSGGLHLHLK 160
DB 112 -WRVLTPGAWSVDQDQPGQLFPMVLLVFLLLGGAWYLQLQ 150

RESULT 13

US-09-971-980-43
; Sequence 43, Application US/09971980
; Patent No. US20020164349A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Yang, Joo-Sung
; TITLE OF INVENTION: Compositions and Methods of Using Capsid Protein From Flaviviruses
; FILE REFERENCE: Upn-4105
; CURRENT APPLICATION NUMBER: US/09/971,980
; CURRENT FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: 60/237,885
; PRIOR FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 43
; LENGTH: 44
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20020164349A1el Sequence
US-09-971-980-43

Query Match 26.5%; Score 214; DB 3; Length 44;
Best Local Similarity 95.7%; Pred. No. 1.6e-15;
Matches 44; Conservative 0; Mismatches 0; Indels 2; Gaps 2;

QY 96 QTEDIRDVLRSFMDGFTTLKENIMRFRSPNPGSWVSCQVLLALL 141
DB 1 QTEDIRDVLIR-FMDGFTTLKENIMRFRSPNPGSWVSC-QVLLALL 44

RESULT 14
US-10-966-576-43
; Sequence 43, Application US/10966576
; Publication No. US20050228849A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, David B.
; APPLICANT: Yang, Joo-Sung
; TITLE OF INVENTION: Compositions and Methods of Using Capsid Protein From Flaviviruses
; FILE REFERENCE: Upn-4105
; CURRENT APPLICATION NUMBER: US/10/966,576
; CURRENT FILING DATE: 2004-10-14
; PRIOR APPLICATION NUMBER: US/09/971,980
; PRIOR FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: 60/237,885
; PRIOR FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 43
; LENGTH: 44
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-966-576-43

Query Match 26.5%; Score 214; DB 5; Length 44;
Best Local Similarity 95.7%; Pred. No. 1.6e-15;
Matches 44; Conservative 0; Mismatches 0; Indels 2; Gaps 2;

QY 96 QTEDIRDVLRSFMDGFTTLKENIMRFRSPNPGSWVSCQVLLALL 141
DB 1 QTEDIRDVLIR-FMDGFTTLKENIMRFRSPNPGSWVSC-QVLLALL 44

RESULT 15
US-09-828-870-12
; Sequence 12, Application US/09828870
; Publication No. US20040054129A1
; GENERAL INFORMATION:
; APPLICANT: CHITTENDEN, Thomas D.; and

```

; LUTZ, Robert J.
; TITLE OF INVENTION: NOVEL PEPTIDES AND COMPOSITIONS WHICH
; MODULATE APOPTOSIS
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hale and Dorr
; STREET: 1455 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/828,870
; FILING DATE: 10-Apr-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/236,385
; FILING DATE: 25-JANUARY-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: WIXON, HENRY N.
; REGISTRATION NUMBER: 32,073
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-942-8400
; TELEFAX: 202-942-8484
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-828-870-12

```

```

Query Match      21.9%; Score 177; DB 3; Length 36;
Best Local Similarity 100.0%; Pred.No. 1.2e-11;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      48 LECMEGSDALALRLACIGDEMDSLRAPRLAQLSEV 83
Db      1 LECMEGSDALALRLACIGDEMDSLRAPRLAQLSEV 36

```

```

Search completed: March 15, 2006, 19:17:18
Job time : 168 secs

```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2006, 19:14:40 ; Search time 23 Seconds
(without alignments)
199.116 Million cell updates/sec

Title: US-10-816-698-3

Perfect score: 809

Sequence: 1 MSEVRLSRDLMTETLLEQ.....LLLLALLPLSLGGLHLLK 160

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 169630 seqs, 28622889 residues

Total number of hits satisfying chosen parameters: 169630

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /cgn2_6/ptodata/1/pubpaa/US08 NEW PUB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US06 NEW PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US07 NEW PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/ECT NEW PUB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US09 NEW PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US10 NEW PUB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US11 NEW PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US60_NEW PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	DB ID	Description
1	98	12.1	20	6	US-10-981-873-8
2	89	11.0	20	6	US-10-981-873-78
3	87	10.8	18	6	US-10-981-873-10
4	84.5	10.4	775	7	US-11-087-099-483
5	82.5	10.2	1045	7	US-11-113-424-54
6	82.5	10.2	1094	6	US-10-821-234-1097
7	82.5	10.2	2376	7	US-11-096-051-4
8	82.5	10.2	2715	7	US-11-096-051-2
9	82.5	10.2	2715	7	US-11-113-424-51
10	82.5	10.2	2721	7	US-11-096-051-10
11	82.5	10.2	2725	7	US-11-096-051-8
12	75	9.3	286	7	US-11-055-822-44
13	75	9.3	340	6	US-10-067-974-8
14	75	9.3	340	7	US-11-055-822-42
15	75	9.3	498	7	US-11-024-959-516
16	73.5	9.1	1519	7	US-11-182-016-5
17	71.5	8.8	323	6	US-10-485-517-251
18	71.5	8.8	334	7	US-11-010-795-1
19	71	8.8	389	7	US-11-010-795-3
20	71	8.8	389	7	US-11-010-795-16
21	70.5	8.7	388	7	US-11-010-795-4
22	70.5	8.7	391	7	US-11-010-795-2
23	70.5	8.7	1145	7	US-11-087-099-11401
24	70.5	8.7	1156	7	US-11-087-099-4316
25	70	8.7	14	6	US-10-981-873-49

26	69	8.5	1246	6	US-10-330-773-409	Sequence 409, Appl
27	68.5	8.5	258	6	US-10-877-346-75	Sequence 75, Appl
28	68.5	8.5	271	6	US-10-353-783-52	Sequence 52, Appl
29	68.5	8.5	751	7	US-11-087-099-4864	Sequence 4864, Ap
30	68	8.4	1177	7	US-11-115-639-22	Sequence 22, Appl
31	68	8.4	1177	7	US-11-115-639-23	Sequence 23, Appl
32	68	8.4	1177	7	US-11-115-639-24	Sequence 24, Appl
33	68	8.4	1177	7	US-11-115-639-25	Sequence 25, Appl
34	68	8.4	1177	7	US-11-115-639-26	Sequence 26, Appl
35	68	8.4	1177	7	US-11-115-639-27	Sequence 27, Appl
36	68	8.4	1177	7	US-11-115-639-28	Sequence 28, Appl
37	68	8.4	1177	7	US-11-115-639-29	Sequence 29, Appl
38	68	8.4	1177	7	US-11-115-639-30	Sequence 30, Appl
39	68	8.4	1242	6	US-10-330-773-412	Sequence 412, App
40	67.5	8.3	1131	7	US-11-087-099-3711	Sequence 3711, Ap
41	67	8.3	1193	7	US-11-115-639-20	Sequence 19, Appl
42	67	8.3	1193	7	US-11-115-639-21	Sequence 20, Appl
43	67	8.3	1193	7	US-11-115-639-21	Sequence 21, Appl
44	66.5	8.2	218	6	US-10-714-887-158	Sequence 158, App
45	66.5	8.2	397	7	US-11-087-099-12425	Sequence 12425, A

ALIGNMENTS

RESULT 1
US-10-981-873-8
; Sequence 8, Application US/10981873
; Publication No. US20050250680A1
; GENERAL INFORMATION:
; APPLICANT: Walensky, Loren D.
; APPLICANT: Korsmeyer, Stanley J.
; APPLICANT: Verdine, Gregory
; TITLE OF INVENTION: STABILIZED ALPHA HELICAL PEPTIDES AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 00530-124001
; CURRENT APPLICATION NUMBER: US/10/981,873
; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US 60/517,848
; PRIOR FILING DATE: 2003-11-05
; PRIOR APPLICATION NUMBER: US 60/591,548
; PRIOR FILING DATE: 2004-07-27
; NUMBER OF SEQ ID NOS: 117
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Naturally occurring peptide
US-10-981-873-8

Query Match 12.1%; Score 98; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.00026;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 GSDALALRLACIGDEMVSLSL 72

Db 1 GSDALALRLACIGDEMVSLSL 20

RESULT 2
US-10-981-873-78
; Sequence 78, Application US/10981873
; Publication No. US20050250680A1
; GENERAL INFORMATION:
; APPLICANT: Walensky, Loren D.
; APPLICANT: Korsmeyer, Stanley J.
; APPLICANT: Verdine, Gregory
; TITLE OF INVENTION: STABILIZED ALPHA HELICAL PEPTIDES AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 00530-124001
; CURRENT APPLICATION NUMBER: US/10/981,873

```

; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US 60/517,848
; PRIOR FILING DATE: 2003-11-05
; PRIOR APPLICATION NUMBER: US 60/591,548
; PRIOR FILING DATE: 2004-07-27
; NUMBER OF SEQ ID NOS: 117
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 78
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Naturally occurring peptide
US-10-981-873-78

Query Match 11.0%; Score 89; DB 6; Length 20;
Best Local Similarity 90.9%; Pred. No. 0.0023;
Matches 20; Conservative 0; Mismatches 0; Indels 2; Gaps 1;

Qy 51 MEGSDALRLACIGDMDVSL 72
Db 1 MEGSD--ALRLACIGDMDVSL 20

RESULT 3
US-10-981-873-10
; Sequence 10, Application US/10981873
; Publication No. US20050250680A1
; GENERAL INFORMATION:
; APPLICANT: Walensky, Loren D.
; APPLICANT: Korsmeyer, Stanley J.
; APPLICANT: Verdine, Gregory
; TITLE OF INVENTION: STABILIZED ALPHA HELICAL PEPTIDES AND
; FILE OF INVENTION: USES THEREOF
; FILE REFERENCE: 00530-124001
; CURRENT APPLICATION NUMBER: US/10/981,873
; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US 60/517,848
; PRIOR FILING DATE: 2003-11-05
; PRIOR APPLICATION NUMBER: US 60/591,548
; PRIOR FILING DATE: 2004-07-27
; NUMBER OF SEQ ID NOS: 117
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Naturally occurring peptide
US-10-981-873-10

Query Match 10.8%; Score 87; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0033;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 56 ALALRLACIGDMDVSLR 73
Db 1 ALALRLACIGDMDVSLR 18

RESULT 4
US-11-087-099-483
; Sequence 483, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 483
; LENGTH: 775

```

```

; TYPE: PRT
; ORGANISM: Nostoc punctiforme
US-11-087-099-483

Query Match 10.4%; Score 84.5; DB 7; Length 775;
Best Local Similarity 26.2%; Pred. No. 0.83;
Matches 27; Conservative 25; Mismatches 36; Indels 15; Gaps 4;

Qy 37 EDLDPMEDFSLCEMGS DALALRLACIGDMDVSLRAPRLAQISEVAMHSLGLAFIYDQ 96
Db 555 EDYAQVLDDDGIECLQTVVLSVR-----METLINA--LLRLSQ-----LGAHLREQ 600

Qy 97 TEDIRDVLRSMFGDTFTLKENI-MRFWRSPNPGSWSCQVIL 138
Db 601 ATDLNELLNQVIDVFRASRQSGLVDIRIPPLPTIQCDRLV 643

RESULT 5
US-11-113-424-54
; Sequence 54, Application US/11113424
; Publication No. US20050260713A1
; GENERAL INFORMATION:
; APPLICANT: Gargolli et al.
; TITLE OF INVENTION: Polypeptides and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-225
; CURRENT APPLICATION NUMBER: US/11/113,424
; CURRENT FILING DATE: 2005-04-21
; PRIOR APPLICATION NUMBER: 60/256,704
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: 60/311,590
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 60/257,314
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 60/311,613
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 60/315,617
; PRIOR FILING DATE: 2001-08-29
; PRIOR APPLICATION NUMBER: 60/307,506
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/322,358
; PRIOR FILING DATE: 2001-09-14
; PRIOR APPLICATION NUMBER: 60/294,075
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: 60/288,153
; PRIOR FILING DATE: 2001-05-02
; NUMBER OF SEQ ID NOS: 190
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 1045
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-113-424-54

Query Match 10.2%; Score 82.5; DB 7; Length 1045;
Best Local Similarity 24.3%; Pred. No. 2;
Matches 25; Conservative 15; Mismatches 42; Indels 21; Gaps 2;

Qy 13 METL-----LYEQLEPPPTMEVLGTDSEEDLDPMEDFSLCEMGS DALALRLACIGDEM 68
Db 248 MQTIRSIGYRNINYPPEASIIITDNE-----EGLLIQTAFLGTSR 290

Qy 69 DVSLRAPRLAQISEVAMHSLGLAFIYDQTEDIRDVLRSMFGDF 111
Db 291 RLVFKYRRQRLSEILYDSTRVSYTIDTAGVLKTVNLQSDGF 333

RESULT 6
US-10-821-234-1097
; Sequence 1097, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit

```


APPLICANT: Andarmani, Susan
APPLICANT: Tang, Y. Tom
TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
FILE REFERENCE: 821A

CURRENT APPLICATION NUMBER: US/10/821,234

PRIOR FILING DATE: 2004-04-07

PRIOR APPLICATION NUMBER: US 60/462,047

NUMBER OF SEQ ID NOS: 1704

SOFTWARE: pt_seq_genes Version 1.0

SEQ ID NO 1097

LENGTH: 1094

TYPE: PRT

ORGANISM: Homo sapiens

US-10-821-234-1097

Query Match 10.2%; Score 82.5; DB 6; Length 1094;

Best Local Similarity 24.3%; Pred. No. 2.1;

Matches 25; Conservative 15; Mismatches 42; Indels 21; Gaps 2;

QY 13 METL-----LYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALRLACIGDEM 68

DB 297 MQTIRSIGYRNYNPPESNAsIITDYN-----EGLLQTAFLGTGR 339

QY 69 DVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGF 111

DB 340 RVLFKYRQTRLSEILYDSTRVSFYDETAGVLKTVNLQSDGF 382

RESULT 7

US-11-096-051-4

Sequence 4, Application US/11096051

Publication No. US20050244868A1

GENERAL INFORMATION:

APPLICANT: Kekuda, Ramesh

APPLICANT: MacLachlan, Timothy K

APPLICANT: Rastelli, Luca

APPLICANT: Vernet, Corine

APPLICANT: Ettenberg, Seth

TITLE OF INVENTION: Ten-M3 Polypeptides and Polynucleotides and their Methods of Use

FILE-REFERENCE: Attorney Docket No. Cura 967

CURRENT APPLICATION NUMBER: US/11/096,051

CURRENT FILING DATE: 2005-03-30

PRIOR APPLICATION NUMBER: 10/038,854

PRIOR FILING DATE: 2001-12-31

PRIOR APPLICATION NUMBER: 10/455,772

PRIOR FILING DATE: 2003-06-04

PRIOR APPLICATION NUMBER: 60/557,978

PRIOR FILING DATE: 2004-03-30

NUMBER OF SEQ ID NOS: 38

SOFTWARE: CuraseqList version 0.1

SEQ ID NO 4

LENGTH: 2376

TYPE: PRT

ORGANISM: Homo sapiens

US-11-096-051-4

Query Match 10.2%; Score 82.5; DB 7; Length 2376;

Best Local Similarity 24.3%; Pred. No. 5.8;

Matches 25; Conservative 15; Mismatches 42; Indels 21; Gaps 2;

QY 13 METL-----LYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALRLACIGDEM 68

DB 1579 MQTIRSIGYRNYNPPESNAsIITDYN-----EGLLQTAFLGTGR 1621

QY 69 DVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGF 111

DB 1622 RVLFKYRQTRLSEILYDSTRVSFYDETAGVLKTVNLQSDGF 1664

RESULT 8

US-11-096-051-2

Sequence 2, Application US/11096051

Publication No. US20050244868A1
GENERAL INFORMATION:
APPLICANT: Kekuda, Ramesh
APPLICANT: MacLachlan, Timothy K
APPLICANT: Rastelli, Luca
APPLICANT: Vernet, Corine
APPLICANT: Ettenberg, Seth
TITLE OF INVENTION: Ten-M3 Polypeptides and Polynucleotides and their Methods of Use
FILE REFERENCE: Attorney Docket No. Cura 967
CURRENT APPLICATION NUMBER: US/11/096,051
CURRENT FILING DATE: 2005-03-30
PRIOR APPLICATION NUMBER: 10/038,854
PRIOR FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: 10/455,772
PRIOR FILING DATE: 2003-06-04
PRIOR APPLICATION NUMBER: 60/557,978
PRIOR FILING DATE: 2004-03-30
NUMBER OF SEQ ID NOS: 38
SOFTWARE: CuraseqList version 0.1
SEQ ID NO 2
LENGTH: 2715
TYPE: PRT
ORGANISM: Homo sapiens
US-11-096-051-2

Query Match 10.2%; Score 82.5; DB 7; Length 2715;

Best Local Similarity 24.3%; Pred. No. 6.9;

Matches 25; Conservative 15; Mismatches 42; Indels 21; Gaps 2;

QY 13 METL-----LYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALRLACIGDEM 68

DB 1918 MQTIRSIGYRNYNPPESNAsIITDYN-----EGLLQTAFLGTGR 1960

QY 69 DVSRLAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGF 111

DB 1961 RVLFKYRQTRLSEILYDSTRVSFYDETAGVLKTVNLQSDGF 2003

RESULT 9

US-11-113-424-51

Sequence 51, Application US/11113424

Publication No. US20050260713A1

GENERAL INFORMATION:

APPLICANT: Gangolli et al.

TITLE OF INVENTION: Polypeptides and Nucleic Acids Encoding Same

FILE REFERENCE: 21402-225

CURRENT APPLICATION NUMBER: US/11/113,424

CURRENT FILING DATE: 2005-04-21

PRIOR APPLICATION NUMBER: 60/256,704

PRIOR FILING DATE: 2000-12-19

PRIOR APPLICATION NUMBER: 60/311,590

PRIOR FILING DATE: 2001-08-10

PRIOR APPLICATION NUMBER: 60/257,314

PRIOR FILING DATE: 2000-12-20

PRIOR APPLICATION NUMBER: 60/311,613

PRIOR FILING DATE: 2001-08-10

PRIOR APPLICATION NUMBER: 60/315,617

PRIOR FILING DATE: 2001-08-29

PRIOR APPLICATION NUMBER: 60/307,506

PRIOR FILING DATE: 2001-07-24

PRIOR APPLICATION NUMBER: 60/322,358

PRIOR FILING DATE: 2001-09-14

PRIOR APPLICATION NUMBER: 60/294,075

PRIOR FILING DATE: 2001-05-29

PRIOR APPLICATION NUMBER: 60/288,153

PRIOR FILING DATE: 2001-05-02

NUMBER OF SEQ ID NOS: 190

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 51

LENGTH: 2715

TYPE: PRT

ORGANISM: Mus musculus

US-11-113-424-51

QY 72 LRAPLAQSEVAMHSLGLAFIYDQTEDIRDV--LRSPMDGFTTLKENIMRFRSPNPGS 129
 Db 94 EQAPKFAQ-----PMDLVGIFSRATLDTKTPFVDVADVKHADDVDFVFLCMGSAATDIP 143

QY 130 WVSCEQVLLALL 142
 Db 144 F-SINRVYAAAVL 155

RESULT 13

US-10-067-974-8
 ; Sequence 8, Application US/10067974
 ; Publication No. US20050250937A9
 ; GENERAL INFORMATION:
 ; APPLICANT: Li, Lihng-Yew
 ; APPLICANT: Trei, Kelli J.
 ; TITLE OF INVENTION: Polynucleotide Constructs for Increased Lysine Production
 ; FILE REFERENCE: 1533.2640001
 ; CURRENT APPLICATION NUMBER: US/10/067,974
 ; CURRENT FILING DATE: 2002-02-08
 ; PRIOR APPLICATION NUMBER: 60/267,183
 ; PRIOR FILING DATE: 2001-02-08
 ; NUMBER OF SEQ ID NOS: 25
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 8
 ; LENGTH: 340
 ; TYPE: PRT
 ; ORGANISM: Corynebacterium glutamicum
 US-10-067-974-8

Query Match 9.3%; Score 75; DB 6; Length 340;
 Best Local Similarity 24.1%; Pred. No. 2.8; Mismatches 58; Indels 18; Gaps 5;
 Matches 32; Conservative 25;

QY 13 METLLYEQLLEPPTMEVLGMDTSEEDLPMD--FDSLECMGSDALALRLACIGDEMVDVS 71
 Db 38 VEKLIQKQ-----PMDLVGIFSRATLDTKTPFVDVADVKHADDVDFVFLCMGSAATDIP 93

QY 72 LRAPLAQSEVAMHSLGLAFIYDQTEDIRDV--LRSPMDGFTTLKENIMRFRSPNPGS 129
 Db 94 EQAPKFAQ-----PMDLVGIFSRATLDTKTPFVDVADVKHADDVDFVFLCMGSAATDIP 143

QY 130 WVSCEQVLLALL 142
 Db 144 F-SINRVYAAAVL 155

RESULT 14

US-11-055-822-42
 ; Sequence 42, Application US/11055822
 ; Publication No. US20050260707A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pompeius, Markus
 ; APPLICANT: Kroger, Burkhard
 ; APPLICANT: Schroder, Hartwig
 ; APPLICANT: Zelder, Oskar
 ; APPLICANT: Haberhauer, Gregor
 ; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
 ; FILE REFERENCE: BGI-121CPCN
 ; CURRENT APPLICATION NUMBER: US/11/055,822
 ; CURRENT FILING DATE: 2005-02-11
 ; PRIOR APPLICATION NUMBER: 09/606,740
 ; PRIOR FILING DATE: 2000-06-23
 ; PRIOR APPLICATION NUMBER: 60/141,031
 ; PRIOR FILING DATE: 1999-06-25
 ; PRIOR APPLICATION NUMBER: 60/142,101
 ; PRIOR FILING DATE: 1999-07-02
 ; PRIOR APPLICATION NUMBER: 60/148,613
 ; PRIOR FILING DATE: 1999-08-12
 ; PRIOR APPLICATION NUMBER: 60/187,970
 ; PRIOR FILING DATE: 2000-03-09

; PRIOR APPLICATION NUMBER: DE 19930476.9
 ; PRIOR FILING DATE: 1999-07-01
 ; PRIOR APPLICATION NUMBER: DE 19931415.2
 ; PRIOR FILING DATE: 1999-07-08
 ; PRIOR APPLICATION NUMBER: DE 19931418.7
 ; PRIOR FILING DATE: 1999-07-08
 ; PRIOR APPLICATION NUMBER: DE 19931419.5
 ; PRIOR FILING DATE: 1999-07-08
 ; PRIOR APPLICATION NUMBER: DE 19931420.9
 ; PRIOR FILING DATE: 1999-07-08
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 1158
 ; SEQ ID NO 42
 ; LENGTH: 340
 ; TYPE: PRT
 ; ORGANISM: Corynebacterium glutamicum
 US-11-055-822-42

Query Match 9.3%; Score 75; DB 7; Length 340;
 Best Local Similarity 24.1%; Pred. No. 2.8; Mismatches 58; Indels 18; Gaps 5;
 Matches 32; Conservative 25;

QY 13 METLLYEQLLEPPTMEVLGMDTSEEDLPMD--FDSLECMGSDALALRLACIGDEMVDVS 71
 Db 38 VEKLIQKQ-----PMDLVGIFSRATLDTKTPFVDVADVKHADDVDFVFLCMGSAATDIP 93

QY 72 LRAPLAQSEVAMHSLGLAFIYDQTEDIRDV--LRSPMDGFTTLKENIMRFRSPNPGS 129
 Db 94 EQAPKFAQ-----PMDLVGIFSRATLDTKTPFVDVADVKHADDVDFVFLCMGSAATDIP 143

QY 130 WVSCEQVLLALL 142
 Db 144 F-SINRVYAAAVL 155

RESULT 15

US-11-024-959-516
 ; Sequence 516, Application US/11024959
 ; Publication No. US20060010516A1
 ; GENERAL INFORMATION:
 ; APPLICANT: FORSTER, RICHARD L.
 ; APPLICANT: CONNETT, MARIE B.
 ; APPLICANT: EMERSON, SARAH JANE
 ; APPLICANT: GRIGOR, MURRAY ROBERT
 ; APPLICANT: HIGGINS, COLLEEN M.
 ; APPLICANT: LUND, STEVEN TROY
 ; APPLICANT: MAGUSIN, ANDREAS
 ; APPLICANT: KODRZYCKI, BOB
 ; TITLE OF INVENTION: CELL CYCLE GENES AND RELATED METHODS
 ; FILE REFERENCE: 04463-0360
 ; CURRENT APPLICATION NUMBER: US/11/024,959
 ; CURRENT FILING DATE: 2004-12-30
 ; PRIOR APPLICATION NUMBER: 60/533,036
 ; PRIOR FILING DATE: 2003-12-30
 ; NUMBER OF SEQ ID NOS: 782
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 516
 ; LENGTH: 498
 ; TYPE: PRT
 ; ORGANISM: Eucalyptus sp.
 US-11-024-959-516

Query Match 9.3%; Score 75; DB 7; Length 498;
 Best Local Similarity 28.2%; Pred. No. 4.6; Mismatches 37; Indels 24; Gaps 6;
 Matches 31; Conservative 18;

QY 20 QLLEPPTMEVL-----GMTDSEEDLPMD--FDSLECMGSDALALRLACIGDEMVDVS- 72
 Db 18 EVAEPSPKEIEILKSGVVERSGSDGEEDENM-----DAVASEKA---DEVSTALS 68

QY 73 RAPRLAQSEVAMHSLGLAFIYDQTEDIRDVLRSP--MDGFTTLKENIMRFRSPNPGS 121
 Db 69 AADALGRISKVKAGSGF-----EDIADGLRELDMDNYDEEDEDVKLIF 111

Search completed: March 15, 2006, 19:17:47
Job time : 24 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model
Run on: March 15, 2006, 19:05:25 ; Search time 188 Seconds
(without alignment)
373.939 Million cell updates/sec

Title: US-10-816-698-3
Perfect score: 809
Sequence: 1 MSEVPLSRDLMTLLYEQ.....LLLLALLPLLSGGLHLLK 160

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq 21:.*
1: geneseqp1980s:.*
2: geneseqp1990s:.*
3: geneseqp2000s:.*
4: geneseqp2001s:.*
5: geneseqp2002s:.*
6: geneseqp2003as:.*
7: geneseqp2003bs:.*
8: geneseqp2004s:.*
9: geneseqp2005s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	809	100.0	160	2	AAW01000 Apoptosis
2	809	100.0	160	2	AAW94326 Human Bip
3	809	100.0	160	2	AAY05436 Human BIK
4	809	100.0	160	7	ADN40055 Cancer/an
5	809	100.0	160	8	ADJ66632 Bcl-2 int
6	809	100.0	160	8	ADL69728 Human Bcl
7	809	100.0	160	8	ADT77553 Wild type
8	809	100.0	160	8	ADU22889 Human apo
9	809	100.0	160	9	ADZ09814 Human bre
10	809	100.0	175	4	AAG74083 Human col
11	809	100.0	175	5	ABP41517 Human ova
12	809	100.0	378	6	AAE37657 Human ova
13	805	99.5	160	8	ADT77558 Ser35Asp
14	803	99.3	160	8	ADT77557 Thr33Asp
15	799	98.8	160	8	ADT77559 Thr33Asp
16	472	58.3	99	3	AAG03648 Human sec
17	284	35.1	150	2	AAY42853 Murine pr
18	284	35.1	150	8	ADT77554 BIK polyD
19	177	21.9	36	5	AAU77887 Bip1a pep
20	177	21.9	36	8	ADK14699 Bak GD do
21	143	17.7	27	8	ABO56845 Human gen
22	142	17.6	28	2	AAW06301 GD domain
23	142	17.6	28	5	AAU77897 Bip1a GD
24	142	17.6	28	8	ADK14717 Bcl-2 rel

25	138	17.1	27	3	AAB37016	Aab37016 Bcl2 poly
26	135	16.7	28	5	AAU77884	Aau77884 Bip1a GD
27	135	16.7	28	8	ADK14696	Adk14696 Bcl-2 rel
28	135	16.7	61	3	AAB53522	Aab53522 Human col
29	135	16.7	61	4	AAG75784	Aag75784 Human col
30	127	15.7	26	3	RAY96324	Ray96324 Mammalian
31	127	15.7	26	4	AAB70374	Aab70374 BIK BH3 C
32	124	15.3	25	9	ABE79162	Abe79162 BH3 pepci
33	122	15.1	27	8	ADT77564	Adt77564 Bik trans
34	108	13.3	22	9	AEA04889	Aea04889 BCL-2 pro
35	100	12.4	20	8	ADK90777	Adk90777 BIKBH3 pe
36	98	12.1	20	5	AAU77896	Aau77896 Bip1a pep
37	98	12.1	20	8	ADK14728	Adk14728 Bcl-2 rel
38	98	12.1	20	9	AEA04818	Aea04818 BCL-2 pro
39	87	10.8	18	8	ADT77563	Adt77563 Bik heter
40	87	10.8	18	8	ADT77562	Adt77562 Bik Bcl-2
41	87	10.8	18	9	AEA04820	Aea04820 BCL-2 pro
42	85	10.5	1908	6	ABJ25817	Abj25817 Aspergill
43	85	10.5	2022	6	ABJ26417	Abj26417 Aspergill
44	84.5	10.4	753	8	ADS41770	Ads41770 Bacterial
45	84	10.4	1120	4	ABB68196	Abb68196 Drosophil

ALIGNMENTS

RESULT 1
AAW01000
ID AAW01000 standard; protein; 160 AA.
XX
AC AAW01000;
XX
DT 18-DEC-1996 (first entry)
XX
DE Apoptosis-regulating protein Bip1A.
XX
KW Apoptosis-regulating protein; Bip1A; adenovirus E1B 19K protein; Bcl-2;
KW oncogene; cell death; cancer; tumour; immune disorder; diagnosis;
KW therapy.
XX
OS Homo sapiens.
XX
PN EP733706-A2.
XX
PD 25-SEP-1996.
XX
PF 21-MAR-1996; 96EP-00104542.
XX
PR 21-MAR-1995; 95US-00408095.
XX
XX (UYSL-) UNIV ST LOUIS.
XX
XX Chinnadurai G;
XX
XX WPI; 1996-427055/43.
XX
XX N-PSDB; AAT38230.
XX
XX Nucleic acids encoding apoptosis regulating proteins - useful for
diagnosing and treating immune disorders, malignancies, etc.
XX
XX Claim 1; Page 47; 60pp; English.
XX
XX Apoptosis-regulating protein Bip1A (AAW01000) specifically interacts with
motifs (see also AAW01003-06) on apoptosis-blocking proteins E1B 19K
CC (AAW01010) and Bcl-2 (AAW01018). Its amino acid sequence was deduced from
CC a cDNA clone (AAT38230) isolated from a human cDNA library using a yeast
CC two-hybrid assay with Bcl-2 as bait. Apoptosis-regulating proteins (see
CC also AAW00997-99 and AAW00101-W01002) can be used diagnostically or to
CC regulate cell death, e.g. to counteract high levels of Bcl-2 associated
XX with certain malignancies
SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 2; Length 160;
 Best Local Similarity 100.0%; Pred. No. 8.4e-88;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120

Qy 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160

RESULT 2
 AAW94326
 ID AAW94326 standard; protein; 160 AA.
 XX
 AC AAW94326;
 XX
 DT 13-APR-1999 (first entry)
 XX
 DE Human BiplA protein.
 XX
 KW Human; Nip1; Nip2; Nip3; BiplA; Bips; Bipl3; adenovirus; cell death;
 KW viral infection; Bcl-2; protooncogene; mutational analysis; apoptosis;
 KW E1B 19K protein; cell survival regulation.
 XX
 OS Homo sapiens.
 XX
 FN US5858678-A.
 XX
 PD 12-JAN-1999.
 XX
 PF 21-MAR-1995; 95US-00408095.
 XX
 PR 02-AUG-1994; 94US-00284139.
 XX
 PA (UYSL-) UNIV ST LOUIS.
 XX
 PI Chinnadurai G;
 XX
 DR WPI; 1999-152099/13.
 DR N-PSDB; AAX04122.
 XX
 PT Polypeptides that bind to anti-apoptotic proteins - useful for protecting
 PT against cell death induced by viral infection and to modulate response to
 PT physical and chemical stimuli.
 XX
 PS Claim 1; Col 61-62; 41pp; English.
 XX
 CC The present invention describes: (1) a method for regulating cell death,
 CC comprising exposing an isolated cell to a polypeptide selected from Nip1,
 CC Nip2, Nip3, BiplA, Bips and Bipl3; (2) a method for neutralising the
 CC activity of the adenovirus E1B 19 kD protein, the Bcl-2 protein or the
 CC BHRF-1 protein, comprising exposing an isolated cell to a polypeptide as
 CC in (1); and (3) a method for detecting molecules that bind to at least
 CC one polypeptide as in (1), comprising lysing cells, exposing the lysate
 CC to the polypeptide and detecting any molecule-polypeptide aggregates.
 CC The methods are useful for providing proteins able to bind to other
 CC proteins known to regulate cell survival e.g. it is known that E1B 19K
 CC protein provides a survival function similar to the cellular
 CC protooncogene bcl-2 gene product which is able to block apoptosis in
 CC haematopoietic B and T cells. The present sequence represents human
 CC BiplA, given in the present invention
 XX
 SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 2; Length 160;
 Best Local Similarity 100.0%; Pred. No. 8.4e-88;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120

Qy 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160

Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120

Qy 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160
 Db 121 FWRSPNPGSWVSCQVLLALLLPLLSGGLHLLK 160

RESULT 3
 AAY05436
 ID AAY05436 standard; peptide; 160 AA.
 XX
 AC AAY05436;
 XX
 DT 02-JUL-1999 (first entry)
 XX
 DE Human BIK protein sequence.
 XX
 KW BH3 domain; cell death agonist; bcl homology domain; BCL-2 family;
 KW apoptosis promoter; cancer cell; virus infected cell; inflammation;
 KW autoantibody producing cell; cancer; lymphoproliferative condition;
 KW arthritis; autoimmune disease; therapy.
 XX
 OS Homo sapiens.
 XX
 FN WO9916787-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 22-SEP-1998; 98WO-US019765.
 XX
 PR 26-SEP-1997; 97US-0060133P.
 PR 07-OCT-1997; 97US-00946039.
 XX
 PA (UNIW) UNIV WASHINGTON.
 XX
 PI Korsmeyer SJ;
 XX
 DR WPI; 1999-255058/21.
 XX
 PT Bcl homology domain 3 polypeptide.
 XX
 PS Disclosure; Fig 21e; 104pp; English.
 XX
 CC This sequence represents the human BIK protein. The invention relates to
 CC a bcl homology domain 3 (BH3 domain), derived from a proapoptotic member
 CC of the BCL-2 family. The BH3 polypeptide can be used in a method for
 CC promoting apoptosis in a target cell, especially where the cell is a
 CC cancer cell a virus infected cell or an autoantibody producing cell. The
 CC BH3 polypeptide can be used in therapeutic compositions for treating
 CC disease including cancer, other lymphoproliferative conditions,
 CC arthritis, inflammation, and autoimmune diseases, which may result from
 CC the down regulation of cell death regulation
 XX
 SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 2; Length 160;
 Best Local Similarity 100.0%; Pred. No. 8.4e-88;
 Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
 Db 1 MSEVRPLSRDILMETLLYEQLLEPTTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

Qy 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120
 Db 61 LACIGDEMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSPMDGFTTLKENIMR 120

Db 61 LACIGDEMVDLSRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120

Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

RESULT 4

ADN40055

ID ADN40055 standard; protein; 160 AA.

XX AC ADN40055;

XX DT 17-JUN-2004 (first entry)

XX DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO: C425.

XX KW Human; differential expression; cancer; angiogenic disorder;

XX KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;

XX KW inflammatory disease; autoimmune disease;

XX KW retinal neovascularisation syndrome; scarring; uterine fibroid;

XX KW detection; diagnosis; prognosis; drug screening; drug targeting;

XX KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;

XX KW vulnery; gene therapy; vaccine.

XX OS Homo sapiens.

XX PN WO2003042661-A2.

XX PD 22-MAY-2003.

XX PF 13-NOV-2002; 2002WO-US036810.

XX PR 13-NOV-2001; 2001US-0350666P.

XX PR 21-NOV-2001; 2001US-0332464P.

XX PR 29-NOV-2001; 2001US-0334393P.

XX PR 03-DEC-2001; 2001US-0335394P.

XX PR 14-DEC-2001; 2001US-0340376P.

XX PR 08-JAN-2002; 2002US-0347211P.

XX PR 10-JAN-2002; 2002US-0347349P.

XX PR 08-FEB-2002; 2002US-035250P.

XX PR 13-FEB-2002; 2002US-0356714P.

XX PR 20-FEB-2002; 2002US-0359077P.

XX PR 29-MAR-2002; 2002US-0368809P.

XX PR 04-APR-2002; 2002US-0370110P.

XX PR 12-APR-2002; 2002US-0372246P.

XX PR 05-JUN-2002; 2002US-0386614P.

XX PR 16-JUL-2002; 2002US-0396839P.

XX PR 22-JUL-2002; 2002US-0397775P.

XX PR 22-JUL-2002; 2002US-0397845P.

XX PR 09-SEP-2002; 2002US-0409450P.

XX (BOS-) EOS BIOTECHNOLOGY INC.

XX AFar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;

XX Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;

XX WPI; 2003-468649/44.

XX N-PSDB; ADN39838.

XX Determining the presence or absence of a pathological cell in a patient.

XX useful for diagnosing, prognosing or treating cancer, comprises detecting

XX a nucleic acid in a biological sample.

XX Claim 12; SEQ ID NO C425; 1385pp; English.

XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)

XX whose expression is upregulated or downregulated in specific cancers or

XX other diseases such as angiogenic or fibrotic disorders, and to methods

XX of determining the presence or absence of a pathological cell in a

XX patient by detecting a nucleic acid at least 80% identical to those of

XX the invention or by detecting a polypeptide of the invention. The

XX invention also relates to expression vectors and host cells comprising a

CC nucleic acid of the invention; antibodies which specifically bind a

CC polypeptide of the invention; use of such antibodies for drug targeting;

CC and methods of screening for modulators of activity or expression of the

CC polypeptides and nucleic acids. The nucleic acids, polypeptides,

CC antibodies and methods are useful for diagnosing, prognosing and treating

CC cancer and other conditions such as psoriasis, ischaemia, heart disease,

CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal

CC neovascularisation syndromes, scarring and uterine fibroids. They may

CC also be useful in wound healing and in contraception. The present

CC sequence represents a polypeptide of the invention.

XX Sequence 160 AA;

Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDEEDLPNEDFDSLECMGSDALALR 60

Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTDEEDLPNEDFDSLECMGSDALALR 60

Qy 61 LACIGDEMVDLSRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120

Db 61 LACIGDEMVDLSRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120

Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

RESULT 5

ADJ66632

ID ADJ66632 standard; protein; 160 AA.

XX AC ADJ66632;

XX DT 06-MAY-2004 (first entry)

XX DE Bcl-2 interacting killer (Bik) protein for anti-cancer protein complex.

XX KW neuroprotective; cytostatic; gene therapy; protein complex;

XX KW cellular network; cancer; neurodegenerative disease; drug target.

XX OS Homo sapiens.

XX PN WO2004009622-A2.

XX PD 29-JAN-2004.

XX PF 18-JUL-2003; 2003WO-EP007835.

XX PR 19-JUL-2002; 2002EP-00016109.

XX PR 19-JUL-2002; 2002EP-00016111.

XX PR 19-JUL-2002; 2002EP-00016123.

XX PR 19-JUL-2002; 2002EP-00016128.

XX PR 22-JUL-2002; 2002EP-00016427.

XX (CELL-) CELLZONE AG.

XX Merino A, Bouwmeester T, Bauer A, Drewes G, Marzioch M, Kruse U;

XX Superti-Furga G, Eberhard D, Ruffner H, Hobson S, Helftenbein G;

XX Cruciat C;

XX WPI; 2004-123372/12.

XX New protein complexes of cellular networks underlying the development of

XX cancer and other diseases, useful for diagnosing and/or treating

XX neurodegenerative diseases or cancer, and in drug screening.

XX Disclosure; SEQ ID NO 162; 809pp; English.

XX The invention relates to a protein complex of cellular networks

XX underlying the development of cancer and other diseases. The complex (I)

CC comprises at least one first and second proteins selected from any of the
CC proteins listed in the specification, or their functionally active
CC derivatives, fragments, homologues or variants, the variants being
CC encoded by a nucleic acid that hybridizes to the nucleic acid encoding
CC the protein under low stringency conditions. A complex (II) comprises at
CC least two of the second proteins, where the low stringency conditions
CC comprise hybridization in a buffer comprising 3% formaldehyde, 5 x SSC, 50
CC mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% BSA, 100 microg/ml,
CC denatured salmon sperm DNA, and 10% (wt/vol) dextran sulfate for 18-20
CC hours at 40 deg C, washing in a buffer consisting of 2 x SSC, 25 mM Tris-
CC HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS for 1.5 hours at 55 deg C, and
CC EDTA, and 0.1% SDS for 1.5 hours at 60 deg C. The composition and methods
CC are useful in diagnosing or treating diseases and disorders, preferably
CC neurodegenerative diseases. These may also be used as a drug target or in
CC manufacturing a medicament for the treatment or prevention of the above-
CC mentioned diseases or disorders. The composition may also be used for
CC treating cancer. This sequence represents one of the proteins of the
CC complex of the invention.

XX SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 8; Length 160;
Best Local Similarity 100.0%; Pred. No. 8.4e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGWTSEEDLPMDPDSLECMGSDALALR 60
|||||
DB 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGWTSEEDLPMDPDSLECMGSDALALR 60
|||||
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGFTTLKENIMR 120
|||||
DB 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGFTTLKENIMR 120
|||||
QY 121 FWRSNPGSWVSCQVLLALLLALLPLLSGGLHLK 160
|||||
DB 121 FWRSNPGSWVSCQVLLALLLALLPLLSGGLHLK 160
|||||

RESULT 6

ID ADL69728 standard; protein; 160 AA.
XX ADL69728;
AC ADL69728;
XX 20-MAY-2004 (first entry)
XX Human Bcl2 related protein #8.
XX Bcl2 related protein; therapeutic protein; human.
XX Homo sapiens.
XX US2004043028-A1.
XX 04-MAR-2004.
XX 02-NOV-2001; 2001US-00003632.
XX 02-NOV-2001; 2001US-00003632.
XX (LEEC/) LEE C.
XX (SHIX/) SHI X.
XX (LYCC/) LY C.
XX (MOOR/) MOORE G.
PI Lee C, Shi X, Ly C, Moore G;
XX WPI; 2004-225672/21.
XX New Bcl2 encoding nucleic acids for enhancing growth and/or production of
XX therapeutic or diagnostic proteins from cultured mammalian host cells.

PS Disclosure; SEQ ID NO 8; 42pp; English.
XX The invention relates to a protein expression enhancing Bcl2 related
CC nucleic acid comprising a first nucleic acid encoding at least one
CC expressible protein and a second nucleic acid encoding at least one Bcl2
CC related protein, where expression of the expressible protein is enhanced
CC by transcription or translation of the second nucleic acid. The
CC composition and methods are useful for enhancing growth and/or production
CC of therapeutic or diagnostic proteins from cultured mammalian host cells.
XX The present sequence is human Bcl2 related protein.

SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 8; Length 160;
Best Local Similarity 100.0%; Pred. No. 8.4e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGWTSEEDLPMDPDSLECMGSDALALR 60
|||||
DB 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGWTSEEDLPMDPDSLECMGSDALALR 60
|||||
QY 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGFTTLKENIMR 120
|||||
DB 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVRSFMDGFTTLKENIMR 120
|||||
QY 121 FWRSNPGSWVSCQVLLALLLALLPLLSGGLHLK 160
|||||
DB 121 FWRSNPGSWVSCQVLLALLLALLPLLSGGLHLK 160
|||||

RESULT 7

ID ADT77553 standard; protein; 160 AA.
XX ADT77553;
XX 13-JAN-2005 (first entry)
XX Wild type Bik.
XX Bik; nbk; pro-apoptotic; BH3-only protein; Bcl-2 homology region;
KW BH3 domain; initiator; apoptosis; chromosome 22q; human; breast; colon;
KW cancer; cell proliferative; phosphorylation; protein transduction domain;
KW inhibition; proliferative disorder; hematologic malignancy; sarcoma;
KW leukaemia; lymphoma; myeloma; prostate; ovarian; lung; brain; pancreatic;
KW liver; bladder; gastrointestinal cancer; oestrogen receptor positive;
KW EGF receptor overexpressing; optionally overexpressing Her2/neu-;
KW Akt overexpressing; androgen dependent; restenosis; sensitizing; tumour;
KW chemotherapeutic agent; antitumour activity.
XX Homo sapiens.
XX WO2004089981-A2.
XX 21-OCT-2004.
XX 02-APR-2004; 2004WO-US010342.
XX 02-APR-2003; 2003US-0459901P.
XX (TEXA) UNIV TEXAS SYSTEM.
XX Hung M, Li Y, Wen Y;
PI WPI; 2004-748724/73.
XX N-PSDB; ADT77555, ADT77556.
XX GENBANK; AAC50413, NP_001188, AAF01156, AAC79124, CAA62013, S58214.
XX New mutant Bik polypeptides having anti-cell proliferation activity
XX and/or pro-apoptotic activity useful for the treatment of cancer.
XX Disclosure; SEQ ID NO 3; 152pp; English.

This sequence is encoded by the genomic DNA sequence encoding wild type BIK. BIK, also known as nbk, is one of the pro-apoptotic BH3-only proteins, which have only one of the Bcl-2 homology regions BH3 domains, and have recently been recognised as essential initiators of apoptosis. BIK is located on chromosome 22q. Loss of informative alleles in this region may be related to the development of human breast and colon cancer. The mutant BIK polypeptides of the invention have anti-cell proliferation activity and/or pro-apoptotic activity. Wild type BIK is mutated at either Thr33, Ser35 or both Thr33 and Ser35. These substitutions prevent the phosphorylation of mutant BIK under conditions that would result in phosphorylation of an unsubstituted BIK polypeptide. The mutant BIK polypeptide further comprises a protein transduction domain and is complexed with a lipid. The mutant BIK of the invention is used for inhibiting cell proliferation in the treatment of a proliferative disorder e.g. cancer (such as hematologic malignancies, sarcoma, leukaemia, lymphoma, myeloma, breast, prostate, ovarian, lung, brain, pancreatic, liver, bladder or gastrointestinal cancer (including oestrogen receptor positive, EGF receptor overexpressing, optionally overexpressing Her2/neu-, Akt overexpressing and optionally androgen dependent cancers)) and restenosis in an animal (such as human); and for sensitizing the tumour cell to a chemotherapeutic agent. The mutant BIK polypeptides exhibit anti-cell proliferation activity and/or pro-apoptotic activity i.e. substantially the same or more effective than the native BIK polypeptides and are capable of exhibiting strong antitumour activity in both in vivo and in vitro cells. The polypeptides sensitize the tumour cell to the chemotherapeutic agent and enhance the chemotherapeutic agent-induced apoptosis of the cells, thus are useful for the treatment of resistant tumours.

Query Match 100.0%; Score 809; DB 8; Length 160;
Best Local Similarity 100.0%; Pred. No. 8.4e-88; Indels 0; Gaps 0;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRLSRDILMETLLYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
DB 1 MSEVRLSRDILMETLLYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

QY 61 LACIGDMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
DB 61 LACIGDMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120

QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160
DB 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

RESULT 8
ADU22889
ID ADU22889 standard; protein; 160 AA.
XX ADU22889;
XX ADU22889;
DT 27-JAN-2005 (first entry)
XX Human apoptosis inducing BIK protein.
DE Human apoptosis inducing BIK protein.
XX apoptosis modulation; cytostatic; antiinflammatory; neuroprotective;
KW muscular-gen.; antiarthritic; antirheumatic; antidiabetic;
KW immunosuppressive; cancer; T-lymphocyte; rheumatoid arthritis;
KW insulin dependent diabetes; multiple sclerosis;
KW systemic lupus erythematosus; myasthenia gravis;
KW graft versus host disease; Bik.
XX Homo sapiens.
XX US2004224389-A1.
XX 11-NOV-2004.
XX 14-APR-2004; 2004US-00825282.

27-MAY-1994; 94US-00250478.
26-JAN-1995; 95US-00378507.
29-MAY-1998; 98US-00087195.
17-MAY-1999; 99US-0134416P.
08-DEC-1999; 99US-00456357.
XX (COLS) UNIV COLORADO.
PA Bellgrau D, Duke RC, Schaack JB;
XX WPI; 2004-794697/78.
DR N-85DB; ADU22888.
XX Propagating a recombinant viral vector comprising a nucleic acid sequence
PT encoding an apoptosis-inducing protein by culturing a cell transfected
PT with a recombinant nucleic acid sequence encoding an apoptosis-inhibiting
PT protein.
XX Claim 12; SEQ ID NO 30; 106pp; English.
XX The invention relates to a novel method for propagating a recombinant
CC viral vector comprising a nucleic acid sequence encoding an apoptosis-
CC inducing protein. The method comprises culturing an isolated cell
CC transfected with a recombinant nucleic acid molecule encoding a protein
CC that inhibits apoptosis, operatively linked to a transcription control
CC sequence, and a recombinant viral vector comprising a nucleic acid
CC sequence encoding a protein that induces apoptosis, operatively linked to
CC a transcription control sequence. The method of the invention
CC demonstrates cytostatic, antiinflammatory, neuroprotective, muscular-
CC gen., antiarthritic, antirheumatic, antidiabetic and immunosuppressive
CC applications. The method may be useful for inducing apoptosis in cancer
CC cells or for suppressing a T-lymphocyte-mediated disease, such as,
CC rheumatoid arthritis, insulin dependent diabetes, multiple sclerosis,
CC systemic lupus erythematosus, myasthenia gravis or graft versus host
CC disease. The current sequence is that of the human apoptosis inducing BIK
CC protein of the invention.
XX Sequence 160 AA;
Query Match 100.0%; Score 809; DB 8; Length 160;
Best Local Similarity 100.0%; Pred. No. 8.4e-88; Indels 0; Gaps 0;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSEVRLSRDILMETLLYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
DB 1 MSEVRLSRDILMETLLYEQLEPPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60

QY 61 LACIGDMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
DB 61 LACIGDMVDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120

QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160
DB 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160

RESULT 9
ADZ09814
ID ADZ09814 standard; protein; 160 AA.
XX ADZ09814;
XX ADZ09814;
XX 30-JUN-2005 (first entry)
XX Human breast cancer marker BIK protein.
DE neoplasm; tumor marker; cytostatic; breast tumor; gene therapy; BIK.
XX Homo sapiens.
XX EP1522594-A2.
XX 13-APR-2005.

XX PF 30-JUN-2004; 2004EP-00015374.
XX PR 06-OCT-2003; 2003EP-00022587.
XX PA (FARB) BAYER HEALTHCARE AG.
XX PI Munnes M, Bojar H;
XX WPI; 2005-265481/28.
DR N-PSDB; AD209649.
XX
PT Characterizing the state of a neoplastic disease in a subject by
PT comparing the pattern of determined expression levels of marker genes in
PT a biological sample with reference patterns of expression levels.
XX
PS Disclosure; SEQ ID NO 258; 542pp; English.
XX
CC The invention relates to a novel method for characterizing the state of a
CC neoplastic disease in a subject comprising determining the pattern of
CC expression levels of at least 6, 8,10,15, 20, 30, 47 or 67 marker genes
CC in a biological sample, comparing the pattern of expression levels with
CC reference patterns of expression levels and characterizing the state of
CC the neoplastic disease in the subject from the outcome of the comparison.
CC The method of the invention demonstrates cytostatic applications and may
CC be useful in characterizing the state of a neoplastic disease in a
CC subject, preferably breast cancer, in gene therapy and for screening for
CC compounds having a curative effect on a neoplastic disease. The current
CC sequence is that of the human breast cancer marker BIK protein of the
CC invention which is differentially expressed in neoplastic tissue.
XX
SQ Sequence 160 AA;

Query Match 100.0%; Score 809; DB 9; Length 160;
Best Local Similarity 100.0%; Pred. No. 8.4e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTSEEDLDPMEDFDSLECMGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTSEEDLDPMEDFDSLECMGSDALALR 60
Qy 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLLK 160
Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLLK 160

RESULT 10
AAG74083
ID AAG74083 standard; protein; 175 AA.
AC AAG74083;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen protein SEQ ID NO:4847.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma; chromosome 22.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.
XX
PR 29-SEP-1999; 99US-0157137P.
PR 03-NOV-1999; 99US-0163280P.

XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX WPI; 2001-235357/24.
DR N-PSDB; AAH33514.
XX
PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers.
XX
PS Claim 11; Page 6630-6631; 9803pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where the
CC proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene therapy
CC and vaccine production. N and P may be used in the prevention, diagnosis
CC and treatment of diseases associated with inappropriate P expression. For
CC example, N and P may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of P by expressing inactive proteins or to
CC supplement the patients own production of P. Additionally, N may be used
CC to produce the colon cancer-associated Ps, by inserting the nucleic acids
CC into a host cell and culturing the cell to express the proteins. N and P
CC can be used in the prevention, diagnosis and treatment of colorectal
CC carcinomas and cancers. AAH37196 to AAH37204 and AAB77789 represent
CC sequences used in the exemplification of the present invention. N.B.
CC Pages 666 to 682 and page 7053 of the sequence listing were missing at
CC time of publication, meaning no sequences are present for SEQ ID NO:1027
CC to 1052, 7921 and 7922
XX
SQ Sequence 175 AA;

Query Match 100.0%; Score 809; DB 4; Length 175;
Best Local Similarity 100.0%; Pred. No. 9.5e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTSEEDLDPMEDFDSLECMGSDALALR 60
Db 16 MSEVRPLSRDILMETLLYEQLLEPTMEVLGWTSEEDLDPMEDFDSLECMGSDALALR 75
Qy 61 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 120
Db 76 LACIGDEMDSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDGFTTLKENIMR 135
Qy 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLLK 160
Db 136 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLLK 175

RESULT 11
ABP41517
ID ABP41517 standard; protein; 175 AA.
AC ABP41517;
XX
DT 22-AUG-2002 (first entry)
XX
DE Human ovarian antigen HCOMW35, SEQ ID NO:2649.
XX
KW Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW inflammatory condition; immune disorder; blood disorder;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disorder; urinary system disorder; drug screening;
KW gene therapy; chromosome mapping; forensic analysis;
KW antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW antiinflammatory; gynaecological; reproductive; chromosome 22q13.31.
XX
OS Homo sapiens.

XX WO200200677-A1.
XX 03-JAN-2002.
XX 07-JUN-2001; 2001WO-US018569.
XX 07-JUN-2000; 2000US-0209467P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Birse CE, Rosen CA;
XX WPI; 2002-147878/19.
XX N-FSDB; ABQ54594.
XX
PT Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian
PT cancer), immune disorders, cardiovascular disorders and neurological
PT diseases.
XX
XX Claim 11; SEQ ID NO 2649; 2922pp; English.
XX
XX The invention relates to 2175 novel human ovarian antigens (ABP41054-
XX ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
XX encompasses polypeptides 90% identical and polynucleotides 95% identical
XX to the sequences of the invention. The invention additionally relates to
XX recombinant vectors and host cells comprising human ovarian antigen
XX polynucleotides, antibodies against human ovarian antigens, and the use
XX of ovarian antigen polynucleotides and polypeptides in diagnosing,
XX treating, prognosing or preventing various ovary and/or breast-related
XX disorders. Such conditions include ovarian cancer and breast cancer, and
XX metastatic tumours of ovarian or breast origin, reproductive system
XX disorders (e.g., infertility, disorders of pregnancy, anovulation,
XX polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
XX disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
XX shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
XX vaginitis), immune disorders (e.g., congenital and acquired
XX immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
XX blood-related disorders (e.g., anaemia), cardiovascular disorders,
XX respiratory disorders, neurological disorders, gastrointestinal disorders
XX and urinary system disorders. Ovarian antigen polypeptides and
XX polynucleotides may also be used in screening for compounds which
XX modulate ovarian antigen expression or activity. The polynucleotides may
XX further be used for gene therapy, chromosome mapping, in the
XX identification of individuals and in forensic analysis, and the
XX polypeptides may be used as food additives or to prepare antibodies
XX useful in disease diagnosis, drug targeting and phenotyping. The present
XX sequence represents a human ovarian antigen of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 175 AA;
Query Match 100.0%; Score 809; DB 5; Length 175;
Best Local Similarity 100.0%; Pred. No. 9.5e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
Db 16 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 75
QY 61 LACIGDEMDSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 76 LACIGDEMDSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 135
QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160
Db 136 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 175
RESULT 12

AAE37657
ID AAE37657 standard; protein; 378 AA.
XX
XX AAE37657;
AC
XX 27-AUG-2003 (first entry)
DT
XX Bcl2 related protein #8.
DE
XX Bcl2 related protein; growth; protein expression.
KW
XX Unidentified.
OS
XX WO2003040374-A1.
FN
XX 15-MAY-2003.
PD
XX 02-NOV-2001; 2001WO-US045553.
PF
XX 02-NOV-2001; 2001WO-US045553.
PR
XX (CENZ) CENTOCOR INC.
PA
XX Lee C, Ly C, Moore G, Shi X;
PI
XX WPI; 2003-441576/41.
DR
XX
XX New protein expression enhancing Bcl2 related nucleic acid for producing
PT commercially useful amounts of expressed protein, comprises a nucleic
PT acid that encodes an expressible protein or at least one Bcl2 related
PT protein.
XX
XX Disclosure; Page 54-55; 64pp; English.
PS
XX The invention relates to methods and compositions for enhanced protein
XX expression and/or growth of cultured cells using co-transcription of at
XX least one Bcl2 related protein encoding nucleic acid molecules. The
XX invention is useful in providing enhanced growth of and/or protein
XX production from cultured mammalian host cells used for the production of
XX commercially useful amounts of expressed protein. The present sequence is
XX Bcl2 related protein
SQ Sequence 378 AA;
Query Match 100.0%; Score 809; DB 6; Length 378;
Best Local Similarity 100.0%; Pred. No. 2.7e-87;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
Db 1 MSEVRPLSRDILMETLLYEQLLEPPTMEVLGMDTSEEDLDPMEDFDSLECMGSDALALR 60
QY 61 LACIGDEMDSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
Db 61 LACIGDEMDSLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLVLSFMDGFTTLKENIMR 120
QY 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160
Db 121 FWRSPNPGSWVSCQVLLALLLALLLPLLSGGLHLK 160
RESULT 13
ADT77558
ID ADT77558 standard; protein; 160 AA.
XX
XX ADT77558;
AC
XX 13-JAN-2005 (first entry)
DT
XX Ser35Asp Bik.
DE
XX Bik; nbk; pro-apoptotic; BH3-only protein; Bcl-2 homology region;
KW BH3 domain; initiator; apoptosis; chromosome 22q; human; breast; colon;
KW

cancer; cell proliferation; phosphorylation; protein transduction domain; inhibition; proliferative disorder; hematologic malignancy; sarcoma; leukaemia; lymphoma; myeloma; prostate; ovarian; lung; brain; pancreatic; liver; bladder; gastrointestinal cancer; oestrogen receptor positive; EGF receptor overexpressing; optionally overexpressing Her2/neu-; Akt overexpressing; androgen dependent; restenosis; sensitizing; tumour; chemotherapeutic agent; antitumour activity.

OS Homo sapiens.

XX Key Location/Qualifiers

XX FT Misc-difference 35

XX FT /label= S35D

XX WO2004089981-A2.

XX 21-OCT-2004.

XX 02-APR-2004; 2004WO-US010342.

XX 02-APR-2003; 2003US-0459901P.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Hung M, Li Y, Wen Y;

XX WPI; 2004-748724/73.

XX New mutant Bik polypeptides having anti-cell proliferation activity and/or pro-apoptotic activity useful for the treatment of cancer.

XX Claim 5; SEQ ID NO 8; 152pp; English.

XX This sequence represents Ser33Asp Bik. Bik, also known as nbk, is one of the pro-apoptotic BH3-only proteins, which have only one of the Bcl-2 homology regions, BH3 domains, and have recently been recognised as essential initiators of apoptosis. Bik is located on chromosome 22q. Loss of informative alleles in this region may be related to the development of human breast and colon cancer. The mutant Bik polypeptides of the invention have anti-cell proliferation activity and/or pro-apoptotic activity. Wild type Bik is mutated at either Thr33, Ser35 or both Thr33 and Ser35. These substitutions prevent the phosphorylation of mutant Bik under conditions that would result in phosphorylation of an unsubstituted Bik polypeptide. The mutant Bik polypeptide further comprises a protein transduction domain and is complexed with a lipid. The mutant Bik of the invention is used for inhibiting cell proliferation in the treatment of a proliferative disorder e.g. cancer (such as hematologic malignancies, sarcoma, leukaemia, lymphoma, myeloma, breast, prostate, ovarian, lung, brain, pancreatic, liver, bladder or gastrointestinal cancer (including oestrogen receptor positive, EGF receptor overexpressing, optionally overexpressing Her2/neu-, Akt overexpressing and optionally androgen dependent cancers)) and restenosis in an animal (such as human); and for sensitizing the tumour cell to a chemotherapeutic agent. The mutant Bik polypeptides exhibit anti-cell proliferation activity and/or pro-apoptotic activity i.e. substantially the same or more effective than the native Bik polypeptides and are capable of exhibiting strong antitumour activity in both in vivo and in vitro cells. The polypeptides sensitize the tumour cell to the chemotherapeutic agent and enhance the chemotherapeutic agent-induced apoptosis of the cells, thus are useful for the treatment of resistant tumours.

XX Sequence 160 AA;

Query Match 99.5%; Score 805; DB 8; Length 160;

Best Local Similarity 99.4%; Pred. No. 2.5e-87;

Matches 159; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MSEVPLSRDILMTLLYEQLLEPTMEVLGWTDSDELDPMEDPDSLECGEGSDALALR 60

DB 1 MSEVPLSRDILMTLLYEQLLEPTMEVLGWTDSDELDPMEDPDSLECGEGSDALALR 60

QY 61 LACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLSFMDGFTTLKENIMR 120

Db 61 LACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLSFMDGFTTLKENIMR 120

QY 121 FWRSPNGSWVSCBOVLALLLLALLLLPLLSGGLHLK 160

Db 121 FWRSPNGSWVSCBOVLALLLLALLLLPLLSGGLHLK 160

RESULT 14

ADT77557

ID ADT77557 standard; protein; 160 AA.

XX AC

XX ADT77557;

XX 13-JAN-2005 (first entry)

XX DT

XX Thr33Asp Bik.

XX DE

XX Bik; nbk; pro-apoptotic; BH3-only protein; Bcl-2 homology region; BH3 domain; initiator; apoptosis; chromosome 22q; human; breast; colon; cancer; cell proliferation; phosphorylation; protein transduction domain; inhibition; proliferative disorder; hematologic malignancy; sarcoma; leukaemia; lymphoma; myeloma; prostate; ovarian; lung; brain; pancreatic; liver; bladder; gastrointestinal cancer; oestrogen receptor positive; EGF receptor overexpressing; optionally overexpressing Her2/neu-; Akt overexpressing; androgen dependent; restenosis; sensitizing; tumour; chemotherapeutic agent; antitumour activity.

XX OS Homo sapiens.

XX Key Location/Qualifiers

XX FT Misc-difference 33

XX FT /label= T33D

XX WO2004089981-A2.

XX 21-OCT-2004.

XX 02-APR-2004; 2004WO-US010342.

XX 02-APR-2003; 2003US-0459901P.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Hung M, Li Y, Wen Y;

XX WPI; 2004-748724/73.

XX New mutant Bik polypeptides having anti-cell proliferation activity and/or pro-apoptotic activity useful for the treatment of cancer.

XX Claim 5; SEQ ID NO 7; 152pp; English.

XX This sequence represents Thr33Asp Bik. Bik, also known as nbk, is one of the pro-apoptotic BH3-only proteins, which have only one of the Bcl-2 homology regions, BH3 domains, and have recently been recognised as essential initiators of apoptosis. Bik is located on chromosome 22q. Loss of informative alleles in this region may be related to the development of human breast and colon cancer. The mutant Bik polypeptides of the invention have anti-cell proliferation activity and/or pro-apoptotic activity. Wild type Bik is mutated at either Thr33, Ser35 or both Thr33 and Ser35. These substitutions prevent the phosphorylation of mutant Bik under conditions that would result in phosphorylation of an unsubstituted Bik polypeptide. The mutant Bik polypeptide further comprises a protein transduction domain and is complexed with a lipid. The mutant Bik of the invention is used for inhibiting cell proliferation in the treatment of a proliferative disorder e.g. cancer (such as hematologic malignancies, sarcoma, leukaemia, lymphoma, myeloma, breast, prostate, ovarian, lung, brain, pancreatic, liver, bladder or gastrointestinal cancer (including oestrogen receptor positive, EGF receptor overexpressing, optionally overexpressing Her2/neu-, Akt overexpressing and optionally androgen dependent cancers)) and restenosis in an animal (such as human); and for sensitizing the tumour cell to a chemotherapeutic agent. The mutant Bik polypeptides exhibit anti-cell proliferation activity and/or pro-

CC apoptotic activity i.e. substantially the same or more effective than the
CC native Bik polypeptides and are capable of exhibiting strong antitumour
CC activity in both in vivo and in vitro cells. The polypeptides sensitize
CC the tumour cell to the chemotherapeutic agent and enhance the
CC chemotherapeutic agent-induced apoptosis of the cells, thus are useful
CC for the treatment of resistant tumours.
XX
SQ

Query Match 99.3%; Score 803; DB 8; Length 160;
Best Local Similarity 99.4%; Pred. No. 4.4e-87;
Matches 159; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MSEVPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDDLPNEDFSLSCMEGSDALALR 60
DB 1 MSEVPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDDLPNEDFSLSCMEGSDALALR 60
QY 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
QY 121 FWRSPNPGSWVSCQVLLALLLALLPLLSGGLHLLK 160
DB 121 FWRSPNPGSWVSCQVLLALLLALLPLLSGGLHLLK 160

RESULT 15
ADT77559
ID ADT77559 standard; protein; 160 AA.
AC ADT77559;
XX
DT 13-JAN-2005 (first entry)
DE
DE Thr33Asp, Ser35Asp Bik.
XX Bik; nbk; pro-apoptotic; BH3-only protein; Bcl-2 homology region;
KW BH3 domain; initiator; apoptosis; chromosome 22q; human; breast; colon;
KW cancer; cell proliferation; phosphorylation; protein transduction domain;
KW inhibition; proliferative disorder; hematologic malignancy; sarcoma;
KW leukaemia; lymphoma; myeloma; prostate; ovarian; lung; brain; pancreatic;
KW liver; bladder; gastrointestinal cancer; oestrogen receptor positive;
KW EGF receptor overexpressing; optionally overexpressing Her2/neu-;
KW Akt overexpressing; androgen dependent; restenosis; sensitizing; tumour;
KW chemotherapeutic agent; antitumour activity.
XX

OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 33 /label= T33D
FT FT
FT Misc-difference 35
FT /label= S35D
XX
PN WO2004089981-A2.
XX
XX 21-OCT-2004.
XX
XX 02-APR-2004; 2004WO-US010342.
XX
XX 02-APR-2003; 2003US-0459901P.
XX
XX (TEXA) UNIV TEXAS SYSTEM.
XX
XX Hung M, Li Y, Wen Y;
XX WPI; 2004-748724/73.
XX
XX New mutant Bik polypeptides having anti-cell proliferation activity
XX and/or pro-apoptotic activity useful for the treatment of cancer.
XX
XX Claim 5; SEQ ID NO 9; 152pp; English.

CC This sequence represents Thr33Asp, Ser35Asp Bik. Bik, also known as nbk,
CC is one of the pro-apoptotic BH3-only proteins, which have only one of the
CC Bcl-2 homology regions, BH3 domains, and have recently been recognised as
CC essential initiators of apoptosis. Bik is located on chromosome 22q. Loss
CC of informative alleles in this region may be related to the development
CC of human breast and colon cancer. The mutant Bik polypeptides of the
CC invention have anti-cell proliferation activity and/or pro-apoptotic
CC activity. Wild type Bik is mutated at either Thr33, Ser35 or both Thr33
CC and Ser35. These substitutions prevent the phosphorylation of an unsubstituted
CC Bik polypeptide. The mutant Bik polypeptide further comprises a protein
CC transduction domain and is complexed with a lipid. The mutant Bik of the
CC invention is used for inhibiting cell proliferation in the treatment of a
CC proliferative disorder e.g. cancer (such as hematologic malignancies,
CC sarcoma, leukaemia, lymphoma, myeloma, breast, prostate, ovarian, lung,
CC brain, pancreatic, liver, bladder or gastrointestinal cancer (including
CC oestrogen receptor positive, EGF receptor overexpressing, optionally
CC overexpressing Her2/neu-, Akt overexpressing and optionally androgen
CC dependent cancer)) and restenosis in an animal (such as human); and for
CC sensitizing the tumour cell to a chemotherapeutic agent. The mutant Bik
CC polypeptides exhibit anti-cell proliferation activity and/or pro-
CC apoptotic activity i.e. substantially the same or more effective than the
CC native Bik polypeptides and are capable of exhibiting strong antitumour
CC activity in both in vivo and in vitro cells. The polypeptides sensitize
CC the tumour cell to the chemotherapeutic agent and enhance the
CC chemotherapeutic agent-induced apoptosis of the cells, thus are useful
CC for the treatment of resistant tumours.
XX
SQ

Sequence 160 AA;

Query Match 98.8%; Score 799; DB 8; Length 160;
Best Local Similarity 98.8%; Pred. No. 1.3e-86;
Matches 158; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 MSEVPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDDLPNEDFSLSCMEGSDALALR 60
DB 1 MSEVPLSRDILMETLLYEQLLEPTMEVLGWTDSSEDDLPNEDFSLSCMEGSDALALR 60
QY 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
DB 61 LACIGDEMDSVLRAPLAQLSEVAMHSLGLAFIYDQTEDIRDLRSFMDGFTTLKENIMR 120
QY 121 FWRSPNPGSWVSCQVLLALLLALLPLLSGGLHLLK 160
DB 121 FWRSPNPGSWVSCQVLLALLLALLPLLSGGLHLLK 160

Search completed: March 15, 2006, 19:08:55
Job time : 190 secs

A-0-5

THIS PAGE BLANK (USPTO)

This Page Blank (uspto)